

Curriculum Vitae Europass



Informazioni personali

Nome(i) / Cognome(i)

Laurino Grossi

Indirizzo(i)

7, VIA MONTE ROMANELLA, 65125 PESCARA, ITALIA

Telefono(i)

Cellulare: +39
3338639579

Fax

E-mail

laurino.grossi@unich.it; rinogrossi62@gmail.com

Cittadinanza

Italiana

CODICE FISCALE

GRSLRN62B07G482I

Luogo e Data di nascita

Pescara 07.02.62

Sesso

M

**Occupazione
desiderata/Settore
professionale**

Esperienza professionale

Date	<p>Dal 1997 al 2005 Ricercatore Universitario presso Università G d'Annunzio Chieti-Pescara, Facoltà di Medicina e Chirurgia, con regime di impiego a tempo pieno.</p> <p>Dal 2005 Professore Associato di Gastroenterologia presso Università G d'Annunzio Chieti-Pescara, Facoltà di Medicina e Chirurgia, con regime di impiego a tempo pieno</p> <p>Dal 2006 Dirigente Medico di I livello c/o Fisiopatologia Digestiva Ospedale Spirito Santo Pescara, come da convenzione ASL Pescara-Università; fino a Settembre 2018 attività assistenziale svolta nell'ambito del Dipartimento di Medicina, aggregato alla pianta organica del Reparto Medicina. Svolge inoltre turni di pronta disponibilità per le urgenze endoscopiche gastroenterologiche nell'ambito del Servizio istituito dalla ASL Pescara. Dal mese di Settembre 2018 incarico di Alta professionalità presso la ASL Pescara, nell'ambito della UOC di Gastroenterologia</p> <p>Dal 1998 a tuttoggi docente di Gastroenterologia nei Corsi di Laurea in Medicina e nelle professioni sanitarie dell'Università G d'Annunzio</p> <p><i>Autore di oltre 200 pubblicazioni di interesse scientifico.</i></p>
Lavoro o posizione ricoperti	Professore Associato Gastroenterologia
Principali attività e responsabilità	<i>Didattica, Ricerca e Assistenza (in convenzione con ASL Pescara)</i>
Nome e indirizzo del datore di lavoro	Università G d'Annunzio Chieti-Pescara, convenzionato ASL Pescara
Tipo di attività o settore	<i>Scuola di Medicina e Scienze della salute (già Facoltà di Medicina e Chirurgia)</i>
Istruzione e formazione	
Date	<p>Diploma maturità classica Liceo Ginnasio G d'Annunzio di Pescara nel Luglio 1980</p> <p>Laurea in Medicina e Chirurgia in data 14.11.86 presso Università G d'Annunzio con voti 110/110 e lode</p>
Titolo della qualifica rilasciata	<p>Nell'anno 1990 ha svolto attività di studio e ricerca presso l'Intestinal Diseases Research Unit della McMaster University di Hamilton, Ontario, Canada, diretto dal Prof. S.M. Collins.</p> <p>Specializzazione in Gastroenterologia ed Endoscopia Digestiva nel Novembre 1991 presso Università G d'Annunzio con voti 70/70 e lode</p> <p>Dottorato di ricerca in Fisiopatologia Gastroenterologica nel Maggio 1998 (Università dell'Aquila, sede consorziata Università G d'Annunzio Chieti)</p>
Principali tematiche/competenze professionali possedute	Particolare esperienza nel campo dei disturbi motori del tratto digestivo e nella gestione delle malattie infiammatorie croniche intestinali-IBD. Competenza nella esecuzione e interpretazione degli esami di manometria esofagea e anoretale, pHmetria e pHimpedenzometria esofagea; esperienza pluriennale nell'uso delle terapie biologiche nei pazienti IBD; responsabile dell'ambulatorio IBD della ASL Pescara. Esperienza pluriennale nel campo dell'endoscopia diagnostica e terapeutica, partecipa attivamente ai turni di reperibilità per le urgenze endoscopiche della ASL Pescara. Consulente per conto di MSD Italia, Abbvie, Takeda, Janssen, Sandoz.
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	
Livello nella classificazione nazionale o internazionale	

Capacità e competenze personali

Madrelingua(e)

Italiana

Altra(e) lingua(e)

Inglese

Autovalutazione

Livello europeo (*)

Comprensione			Parlato			Scritto		
Ascolto		Letture	Interazione orale		Produzione orale			
	eccellente		eccellente		eccellente		eccellente	

Lingua

Lingua

(*) [Quadro comune europeo di riferimento per le lingue](#)

Capacità e competenze sociali

Capacità e competenze organizzative

Capacità e competenze tecniche

Capacità e competenze informatiche

Capacità e competenze artistiche

Altre capacità e competenze

Patente

Patente di guida italiana tipo B per autoveicoli

Ulteriori informazioni

Inserire qui ogni altra informazione utile, ad esempio persone di riferimento, referenze, ecc. (facoltativo, v. istruzioni)

Allegati

Data **29 Agosto 2022**

Firma

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Firma

ELENCO PUBBLICAZIONI

1989

1. PHARMACOLOGICAL PACING OF PHASE III OF MIGRATING MOTOR COMPLEX (MMC)s IN HUMANS. Marzio L, Pieramico O, Dimitri A, Grossi L, Cuccurullo F. Gastroenterology 1989;96,2:A324 (abst).

2. LE DISCINESIE GASTRICHE. Marzio L, Dimitri A, Grossi L. Check-up Incontri 1989;69:14-18.

3. EVALUATION OF REFRACTORY PERIOD OF THE MMC THROUGH PHARMACOLOGICAL PACING OF PHASE III OF MMC IN HUMANS. Marzio L, Pieramico O, Dimitri A, Grossi L, Cuccurullo F. Journal of Gastrointestinal Motility 1989;1:45 (abst).

4. MOUTH TO CECUM TRANSIT TIME IN PATIENTS AFFECTED BY CHRONIC CONSTIPATION: EFFECT OF GLUCOMANNAN. Marzio L, Del Bianco R, Delle Donne M, Pieramico O, Grossi L, Dimitri A, Cuccurullo F. International Symposium on Gastrointestinal Motility-Gmunden (Austria) Sett.10-14, 1989 (abst).

1990

5. CISAPRIDE CORRECTS GALLBLADDER HYPOKINESIA IN DYSPEPTIC PATIENTS: A DOUBLE BLIND CROSS OVER CLINICAL TRIAL. Marzio L, Di Felice F, Laico MG, Celiberti V, Grossi L, Del Bianco R, Cuccurullo F. Second International Meeting on Patochemistry, Pathophysiology and Pathomechanics of the Biliary System and New Strategies for the Treatment of Hepato-biliary Diseases, Bologna, Marzo 19-21, 1990 (abst).

6. GALLBLADDER HYPOKINESIA AND NORMAL GASTRIC EMPTYING OF LIQUIDS IN PATIENTS WITH DISPEPTIC SYMPTOMS: A DOUBLE BLIND PLACEBO CONTROLLED TRIAL WITH CISAPRIDE. Marzio L, Di Felice F, Laico MG, Celibert V, Grossi L, Del Bianco R, Cuccurullo F. Gastroenterology 1990;98,2:A255 (abst).

7. INFLAMMATION ALTERS THE PROPERTIES OF MURINE INTESTINAL SMOOTH MUSCLE. Grossi L, Blennerhassett P, Collins SM. Clinical and Invesigative Medicine 1990;13(suppl),4:B146.

8. CISAPRIDE CORRECTS GALLBLADDER HYPOKINESIA IN DYSPEPTIC PATIENTS WITH NORMAL GASTRIC EMPTYING: A DOUBLE BLIND CROSS OVER CLINICAL TRIAL. Marzio L, Di Felice F, Laico MG, Grossi L, Del Bianco R, Cuccurullo F, Manzi A. International Symposium on Pharmacotherapy of Gastrointestinal Motor Disorders, Adelaide, South Australia, 2-4 Settembre, 1990 (abst).

9. T-LYMPHOCYTE MODULATION OF CHANGES IN INTESTINAL SMOOTH MUSCLE IN MURINE TRICHINOSIS. Grossi L, Blennerhassett P, Ernst PB, Collins SM. 6th Biennial Meeting American Motility Society; Newport, RI, October 14-17, 1990.

10. GALLBLADDER HYPOKINESIA AND NORMAL GASTRIC EMPTYING OF LIQUIDS IN PATIENTS WITH DISPEPTIC SYMPTOMS: A DOUBLE BLIND PLACEBO CONTROLLED TRIAL WITH CISAPRIDE. Marzio L, Di Felice F, Celiberti V, Grossi L, Del Bianco R, Cuccurullo F. Abstracts book of Digestive Diseases Week San Antonio, Texas, 1990 May 13-16: A266 (abst).

11. EFFECT OF CIMETROPIUM BROMIDE ON GALLBLADDER CONTRACTION IN RESPONSE TO ORAL AND INTRADUODENAL OLIVE OIL. Marzio L, Di Felice F, Celiberti V, Pieramico O, Grossi L, Di Gioacchino M, Imbimbo PB, Cuccurullo F. Eur J Clin Pharmacol 1990;39:369-72.

Pagina 4/21 - Curriculum vitae di

12. LA CISAPRIDE CORREGGE L'IPOCINESIA DELLA COLECISTI IN PAZIENTI DISPEPTICI CON NORMALE SVUOTAMENTO GASTRICO. Marzio L, Di Felice F, Laico MG, Grossi L, DelBianco R, Cuccurullo F, Manzi A. Suppl. Gastroenterologia Oggi 1990;4:39-40.

1991

13. STUDIO FUNZIONALE DELLE RESEZIONI RETTALI BASSE. Innocenti P, Costantini R, Genovesi N, Grossi L, Napolitano AM. Atti VI Congresso Nazionale Società Italiana di Fisiopatologia Chirurgica, Chieti, 18-20 Aprile 1991: 251-60.

14. EFFECT OF ERYTHROMYCIN AND MOTILIN IN AN IN VITRO RABBIT INTESTINAL PREPARATION. Marzio L, Grossi L, De Leonardis T, Cuccurullo F. The Italian Journal of Gastroenterology 1991;23,8: 532 (abst).

15. TREATMENT OF HELICOBACTER PYLORI(HP) INFECTION WITH AN ASSOCIATION OF OMEPRAZOLE AND ROXYDROMICINE: A STUDY IN VIVO AND IN VITRO. Marzio L, Cellini L, Grossi L, Di Girolamo A, De Leonardis T, Alameddine M. The Italian Journal of Gastroenterology 1991;23,9(Suppl.2):111 (abst).

16. ENHANCED CLEARING OF HELICOBACTER PYLORI AFTER OMEPRAZOLE PLUS ROXHITROMYCIN TREATMENT. Cellini L, Marzio L, DiGirolamo A, Allocati N, Grossi L and Dainelli B. FEMS Microbiology Letters 1991;84:255-258.

1992

17. 48-HOUR CONTINUOUS PH MEASUREMENT IN PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX: EFFECT OF CISAPRIDE. Marzio L, Grossi L, Alameddine M, Porreca E, Cuccurullo F. Drug Investigation 1992;4,1:62-65.

18. EVALUATION OF THE REFRACTORY PERIOD OF THE HUMAN MMC THROUGH PHARMACOLOGICAL INDUCTION OF PHASE III. Marzio L, Pieramico O, Grossi L, Di Felice F, Nelson DK, Lapenna D, Cuccurullo F. Journal of Gastrointestinal Motility 1992;4,2:99-105.

19. SPONTANEOUS MIGRATING MOTOR COMPLEX IN ISOLATED IN VITRO RABBIT INTESTINAL PREPARATION. Grossi L, Martelli L, Falcucci MA, Marzio L. Journal of Gastrointestinal Motility 1992;4,3:220 (abst).

20. ERYTHROMYCIN AND MOTILIN-INDUCED MIGRATING MOTOR COMPLEX (MMC) IN AN IN VITRO RABBIT INTESTINAL PREPARATION ARE ACETILCHOLINE MEDIATED. Marzio L, Grossi L, Martelli L, Falcucci MA, Alameddine M, Pascali D, De Laurentis MF. Journal of Gastrointestinal Motility 1992;4,3:232 (abst).

1993

21. UNA NUOVA FORMULAZIONE DI CISAPRIDE, GRANULATO EFFERVESCENTE 10 MG, NEL TRATTAMENTO DELLA MALATTIA DA REFLUSSO GASTROESOFAGEO. Grossi L, Di Felice F, Marzio L. Clin Ter 1993;142(2):127-33.

22. EFFICACIA E TOLLERABILITA' DI UNA NUOVA FORMULAZIONE DI CISAPRIDE GRANULATO EFFERVESCENTE 10 MG, NEL TRATTAMENTO DELLA DISPEPSIA FUNZIONALE. Grossi L, Di Felice F, Marzio L. Clin Ter 1993;142(6):521-7.

23. ON THE SPECIFICITY OF ALTERED MUSCLE FUNCTION IN EXPERIMENTAL COLITIS IN RATS. Grossi L, McHugh K, Collins SM. Gastroenterology 1993;104:1049-56.

24. CIMETROPIUM BROMIDE REDUCES ESOPHAGEAL LOWER SPHINCTER PRESSURE AND TRANSIT TIME IN PATIENTS AFFECTED BY PRIMARY ACHALASIA. Marzio L, Cennamo L, DeLaurentiis MF, Grossi L. Digestive Disease Week, Boston, May 16-19, 1993: pag. A-522, n. 2084 (abst).

25. GASTRIC EMPTYING IN DYSPEPTIC PATIENTS WITH HELICOBACTER PYLORI POSITIVE AND NEGATIVE ANTRAL GASTRITIS: EFFECT OF OMEPRAZOLE. Marzio L, Cellini L, DiFelice F, Grossi L. Gastroenterology 1993;104,4(suppl):A547 (abst).

26. CIMETROPIUM BROMIDE REDUCES ESOPHAGEAL LOWER SPHINCTER PRESSURE AND TRANSIT TIME IN PATIENTS AFFECTED BY PRIMARY ACHALASIA. Marzio L, Cennamo L, De Laurentiis MF, Grossi L. Gastroenterology 1993;104,4(suppl):A547 (abst).

27. ROLE OF NITRIC OXIDE ON PERISTALTIC MOTOR ACTIVITY IN AN IN VITRO RABBIT INTESTINAL PREPARATION. Grossi L, Falcucci MA, Lapenna D, Marzio L. Journal of Gastrointestinal Motility 1993;5,3:193 (abst).

28. INTESTINAL MOTILITY AND GALLSTONE DISEASE: EVIDENCE OF A DELAYED TRANSIT TIME BY HYDROGEN BREATH TEST. Grossi L, Falcucci M, DeLaurentis M, Festi D, Marzio L. Journal of Hepatology 1993;18,Suppl 1:S128 (abst).

29. DISTRIBUZIONE TRANSMURALE DEI SISTEMI ANTIOSSIDANTI E DELLA PEROSSIDAZIONE LIPIDICA NEL VENTRICOLO SINISTRO DI CONIGLIO. Lapenna D, Mezzetti A, de Gioia S, Ciofani G, Pierdomenico SD, Consoli A, Grossi L, Cuccurullo F. XCIV Congresso Nazionale Della

Societa'Italiana di Medicina Interna, Roma, 14-18 Ottobre 1993 (abst).

30. RUOLO DELL'OSSIDO NITRICO SULL'ATTIVITA' PERISTALTICA "IN VITRO" NELL'ANSA INTESTINALE DI CONIGLIO. Marzio L, Grossi L, Falcucci M, Lapenna D, Festi D. Gastroenterologia ed Endoscopia Digestiva 1993; Suppl. N. 3 (Settembre-Dicembre), pag. 41 (abst).

31. MOTILITA' INTESTINALE E CALCOLOSI DELLA COLECISTI: EVIDENZA DI UN RALLENTATO TEMPO DI TRANSITO INTESTINALE. Grossi L, Marzio L, Festi D, Falcucci M, Lapenna D. Gastroenterologia ed Endoscopia Digestiva 1993; Suppl. N. 3, (Settembre-Dicembre), pag. 118 (abst).

32. L'ERITROMICINA ACCELERA LO SVUOTAMENTO GASTRICO E COLECISTICO MEDIANTE UN MECCANISMO DI TIPO COLINERGICO NELL'UOMO. Marzio L, Giacobbe A, Facciorusso D, Tonti P, Andriulli A, Lapenna D, Grossi L, Festi D. Gastroenterologia ed Endoscopia Digestiva 1993; Suppl. N. 3 (Settembre-Dicembre), pag. 118 (abst).

33. INTESTINAL MOTILITY AND GALLSTONE DISEASE: EVIDENCE OF A DELAYED INTESTINAL TRANSIT TIME. Grossi L, Marzio L, Festi D, Falcucci M, Lapenna D. The Italian Journal of Gastroenterology 1993; Suppl 1, Vol 25,9:98 (abst).

34. ERYTHROMYCIN ACCELERATES GASTRIC AND GALLBLADDER EMPTYING THROUGH A CHOLINERGIC MEDIATED MECHANISM IN HUMANS. Marzio L, Giacobbe A, Facciorusso D, Tonti P, Andriulli A, Lapenna D, Grossi L, Festi D. The Italian Journal of Gastroenterology 1993; Suppl 1, Vol 25,9:121 (abst).

35. ROLE OF NITRIC OXIDE ON PERISTALTIC MOTOR ACTIVITY IN AN IN VITRO RABBIT INTESTINAL PREPARATION. Marzio L, Grossi L, Falcucci M, Lapenna D, Festi D. The Italian Journal of Gastroenterology 1993; Suppl 1, Vol 25,9:121 (abst).

36. RIFAXIMIN IN THE TREATMENT OF CHRONIC HEPATIC ENCEPHALOPATHY; RESULTS OF A MULTICENTRIC STUDY OF EFFICACY AND SAFETY. Festi D, Mazzella G, Orsini M, Sottili S, Sangermano A, Li Bassi S, Parini P, Ferrieri A, Falcucci M, Grossi L, Marzio L and Roda E. Current Therapeutic Research 1993;54(5):598-609.

1994

37. GASTRIC ULCER AND ANTRAL GASTRITIS EXPERIMENTALLY INDUCED BY HUMAN HELICOBACTER PYLORI IN BACILLARY AND COCCOID FORM IN BALB/C EUTHYMIC MICE. Marzio L, Angelucci D, Allocati N, Iezzi T, Di Campi E, Grossi L, Cellini L. Gastroenterology 1994; 106,4(suppl):A129 (abst).

38. CORRELATION BETWEEN GASTRIC AND GALLBLADDER EMPTYING AND FILLING IN NORMAL SUBJECTS AND PATIENTS WITH IDIOPATHIC DYSPEPSIA. Marzio L, Falcucci M, Grossi L. Gastroenterology 1994;106,4(suppl):A349 (abst).

39. RELATIONSHIP BETWEEN INTERDIGESTIVE ESOPHAGEAL AND GASTRIC MOTILITY IN HUMANS. Marzio L, Grossi L, Falcucci M, Lapenna D, Festi D, Reddy SN. Gastroenterology 1994; 106,4(suppl):A536 (abst).

40. CORRELATION BETWEEN GASTRIC AND GALLBLADDER EMPTYING AND FILLING IN NORMAL SUBJECTS AND PATIENTS WITH IDIOPATHIC DYSPEPSIA. Marzio L, Falcucci M, Grossi L. Neurogastroenterology and Motility 1994;6,4:145 (abst).

41. RELATIONSHIP BETWEEN INTERDIGESTIVE ESOPHAGEAL AND GASTRIC MOTILITY IN HUMANS. Marzio L, Grossi L, Falcucci M, Lapenna D, Festi D, Reddy SN. Neurogastroenterology and Motility 1994; 6,2:167 (abst).

42. CORRELAZIONE TRA CINETICA GASTRICA E COLECISTICA IN SOGGETTI SANI E IN PAZIENTI CON DISPEPSIA IDIOPATICA. Marzio L, Falcucci M, Grossi L. Atti VI Congresso Nazionale GISMAD, Sorrento, 8-10 Settembre 1994:pag.91.

43. RELAZIONI TRA MOTILITA' INTERDIGESTIVA ESOFAGEA E GASTRICA NELL'UOMO. Marzio L, Grossi L, Falcucci M, Lapenna D, Reddy SN. Atti VI Congresso Nazionale GISMAD, Sorrento, 8-10 Settembre 1994:pag.92.

44. EFFECT OF CIMETROPIUM BROMIDE ON ESOPHAGEAL MOTILITY AND TRANSIT IN PATIENTS AFFECTED BY PRIMARY ACHALASIA. Marzio L, Grossi L, De Laurentis MF, Cennamo L, Lapenna D, Cucurullo F. Digestive Diseases and Sciences 1994;39,7:1389-94.

45. HELICOBACTER PYLORI (HP) STATUS AFTER TREATMENT WITH OMEPRAZOLE: PRELIMINARY RESULTS OF LONG TERM TREATMENTS. Biasco G, Cifani F, Falcucci M, Ferrini G, Grossi L, Lattanzio R, Lauri A, Marzio L, Masciulli V, Sacco T, Santucci R, Sciampa G, Sedici A, Spadaccini A. American Journal of Gastroenterology 1994;89,8:1364 (abst).

46. SHORT AND LONG TERM OMEPRAZOLE FOR THE TREATMENT AND PREVENTION OF DUODENAL ULCER AND EFFECT ON HELICOBACTER PYLORI. Marzio L, Biasco G, Cifani F, DeFanis C, Falcucci M, Ferrini G, Grossi L, Iannetti G, Larcinese G, Lattanzio R, Lauri A, Masciulli V, Sacco T, Sciampa G, Sedici A, Semperlotti N, Spadaccini A. American Journal of Gastroenterology 1994;89,8:1380 (abst).

47. SHORT AND LONG TERM OMEPRAZOLE FOR THE TREATMENT AND PREVENTION OF DUODENAL ULCER AND EFFECT ON HELICOBACTER PYLORI. Marzio L, Biasco G, Cifani F, DeFanis C, Di Iorio P, Falcucci M, Ferrini G, Grossi L, Iannetti G, Larcinese G, Lattanzio R, Lauri A, Masciulli V, Sacco T, Sciampa G, Seccia G, Sedici A, Semperlotti N, Spadaccini A. 10th World Congress of Gastroenterology, Los Angeles 2-7 Ottobre 1994 (Atti): abstract 56P.

48. RELATIONSHIP BETWEEN INTERDIGESTIVE ESOPHAGEAL AND GASTRIC MOTILITY IN HUMANS. Marzio L, Grossi L, Falcucci M, Lapenna D, Festi D, Reddy SN. 10th World Congress of Gastroenterology, Los Angeles 2-7 Ottobre 1994 (Atti): abstract 239.

49. MIGRATING MOTOR COMPLEX RECORDED SPONTANEOUSLY AND INDUCED BY MOTILIN AND ERYTHROMYCIN IN AN EX VIVO RABBIT INTESTINAL PREPARATION. Marzio L, Grossi L, Martelli L, Falcucci M, Lapenna D. Peptides 1994;15(6):1067-77.

50. H2-RECEPTOR ANTAGONISTS ARE SCAVENGERS OF OXYGEN RADICALS. Lapenna D, deGioia S, Mezzetti A, Grossi L, Festi D, Marzio L, Cuccurullo F. European Journal of Clinical Investigation 1994; 24:476-481.

51. COMPUTERIZED ORGANIZATION ON A MULTICENTER TRIAL ON DUODENAL ULCER BY ELECTRONIC FORM AND DATA COLLECTION VIA MODEM-TELECOM NETWORK. GASUD (Abruzzo Group for the Study of Duodenal Ulcer) Marzio L, Biasco G, Cifani F, DeFanis C, Falcucci M, Ferrini G, Grossi L, Iannetti G, Larcinese G, Lattanzio R, Lauri A, Manigrasso MR, Masciulli V, Sacco T, Sciampa G, Sedici A, Semperlotti N, Spadaccini A. The Italian Journal of Gastroenterology, Vol. 26, No. 2, Suppl. 2, 1994: Pag. 108.

52. SHORT AND LONG TERM OMEPRAZOLE FOR THE TREATMENT AND PREVENTION OF DUODENAL ULCER AND EFFECT ON HELICOBACTER PYLORI. GASUD (Abruzzo Group for the Study of Duodenal Ulcer) Marzio L, Biasco G, Cifani F, DeFanis C, Falcucci M, Ferrini G, Grossi L, Iannetti G, Larcinese G, Lattanzio R, Lauri A, Masciulli V, Sacco T, Sciampa G, Sedici A, Semperlotti N, Spadaccini A. The Italian Journal of Gastroenterology, Vol. 26, No. 2, Suppl. 2, 1994: Pag. 108.

1995

53. PROLONGED ANAL SPHINCTER MANOMETRY IN NORMAL HUMAN SUBJECTS. Marzio L, Ciccaglione AF, Falcucci M, Malatesta MG, Grossi L. Gastroenterology 1995; 108, 4:A646 (abst).

54. TWO WEEKS REGIMEN WITH AMOXICILLIN, TINIDAZOLE AND OMEPRAZOLE ERADICATES HELICOBACTER PYLORI AND CURES ACTIVE DUODENAL ULCER. Marzio L, Grossi L et al. Gastroenterology 1995; 108, 4:A159 (abst).

55. ALTERAZIONI NON LITIASICHE DEL CONTENUTO COLECISTICO. Festi D, Grossi L. Collana monotematica di ecografia, Ed. Gnocchi, 1995: 7. COLECISTI: 41-49.

56. PHARYNGEAL, ESOPHAGEAL AND GASTRIC MOTILITY IN NORMAL SUBJECTS AND IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. L Grossi, AF Ciccaglione, M Falcucci, MG Malatesta, N. Travaglini. Gut vol 37 (Suppl. n.2), 1995: A202(abst).

57. ANAL CANAL DIAMETERS AND PRESSURE MEASURED SIMULTANEOUSLY BY REL-TIME ULTRASONOGRAPHY AND MANOMETRY IN HUMAN SUBJECTS. L Marzio, AF Ciccaglione, M Falcucci, MG Malatesta, L Grossi, S Guerri. Gut vol. 37(Suppl. n.2), 1995: A203(abst).

58. EFFECT OF OMEPRAZOLE, CLARITHROMICIN AND AMOXICILLIN FOR A SHORT TIME ON HELICOBACTER PYLORI ERADICATION. G Ferrini, M Falcucci, L Grossi, L Marzio et al. Gut vol 37(Suppl n.2), 1995:A247(abst).

59. MOUTH TO CAECUM TRANSIT TIME (MCTT) IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS) AND FOOD HYPERSENSITIVITY. MG Malatesta, G Forlani, AF Ciccaglione, M Falcucci, A Castellano, L Grossi, L Marzio. International Journal of Immunopathology and Pharmacology Vol. 8, N. 3, Sep-Dec 1995.

60. GASTRIC ANTRAL AND FUNDUS RECEPTIVE RELAXATION IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS. M Falcucci, MG Malatesta, AF Ciccaglione, L Grossi, L Marzio. Neurogastroenterology and Motility Vol. 7, 4; 1995: 257(abst).

61. ESOPHAGEAL AND GASTRIC MOTILITY IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. L Grossi, M Falcucci, N Travaglini, AF Ciccaglione, MG Malatesta, L Marzio. Neurogastroenterology and Motility Vol. 7, 4; 1995:260(abst).

62. GASTRIC DISTENTION WITH INCREASING AMOUNTS OF WATER IN NORMAL SUBJECTS AND IN DYSPEPTIC PATIENTS. M Falcucci, MG Malatesta, AF Ciccaglione, L Grossi, L Marzio. The Italian Journal of Gastroenterology 1995; 27, Suppl. 1:100 (abst).

63. EFFECT OF OMEPRAZOLE, CLARITHROMICIN AND AMOXICILLIN FOR A SHORT TIME ON HELICOBACTER PYLORI ERADICATION. G Ferrini, A Angelone, D Angelucci, C DeFanis, A Della Sciucca, M Falcucci, L Grossi, G Iannetti, G Larcinese, R Lattanzio, A Lauri, L Marzio, P Mescia, A Moretta, S Pasto', G Pizzicannella, G Sciampa, N Semperlotti, A Spadaccini. The Italian Journal of Gastroenterology 1995; 27, Suppl. 1:107 (abst).

64. OESOPHAGEAL AND GASTRIC MOTILITY IN PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE. L Grossi, M Falcucci, N

Travaglini, AF Ciccaglione, MG Malatesta, A Castellano, L Marzio. The Italian Journal of Gastroenterology 1995; 27, Suppl. 1:131 (abst).

65. AORTO-ENTERIC FISTULAS: ENDOSCOPIC DIAGNOSIS. A Spadaccini, G Sciampa, C DeFanis, L Grossi. The Italian Journal of Gastroenterology 1995; 27, Suppl. 1:232 (abst).

66. DIAMETERS AND PRESSURES OF THE ANAL CANAL SIMULTANEOUSLY MEASURED WITH ENDOSONOGRAPHY AND MANOMETRY. AF Ciccaglione, S Guerri, MG Malatesta, M Falcucci, L Grossi, N Travaglini, A Castellano, L Marzio. The Italian Journal of Gastroenterology 1995; 27, Suppl. 1:267 (abst).

67. SHORT- AND LONG-TERM OMEPRAZOLE FOR THE TREATMENT AND PREVENTION OF DUODENAL ULCER, AND EFFECT ON HELICOBACTER PYLORI. L Marzio, G Biasco, F Cifani, C DeFanis, M Falcucci, G Ferrini, L Grossi, G Iannetti, G Larcinese, R Lattanzio, A Lauri, V Masciulli, T Sacco, G Sciampa, A Sedici, N Semperlotti, A Spadaccini. Am J Gastroenterol 1995; 90, 12:2172-6.

1996

68. RELATIONSHIP BETWEEN GASTRIC AND GALLBLADDER EMPTYING AND REFILLING IN NORMAL SUBJECTS AND PATIENTS WITH H. PYLORI-POSITIVE AND -NEGATIVE IDIOPATHIC DYSPEPSIA AND CORRELATION WITH SYMPTOMS. L. Marzio, M Falcucci, AF Ciccaglione, MG Malatesta, D Lapenna, E Ballone, C Antonelli, L Grossi. Dig Dis Sci 1996;41(1): 26-31.

69. INCREASE OF SWALLOWS BEFORE ONSET OF PHASE III OF MIGRATING MOTOR COMPLEX IN NORMAL HUMAN SUBJECTS. L Marzio, L Grossi, M Falcucci, AF Ciccaglione, MG Malatesta, D Lapenna. Dig Dis Sci 1996;41(3):522-7.

70. CORRELATION BETWEEN ANAL CANAL SIZE AND ANAL CANAL PRESSURE: AN ULTRASONOGRAPHIC AND MANOMETRIC STUDY. AF Ciccaglione, S Guerri, MG Malatesta, M Falcucci, L Grossi, L Marzio. Gastroenterology 1996;110(4,Suppl):A649(abst).

71. GASTRIC ANTRAL AND FUNDIC DISTENTION EVALUATED BY ULTRASONOGRAPHY (US) IN NORMAL SUBJECTS AND PATIENTS WITH IDIOPATHIC DYSPEPSIA. M Falcucci, MG Malatesta, AF Ciccaglione, A Castellano, N Travaglini, L Grossi, L Marzio. Gastroenterology 1996;110(4,Suppl):A661 (abst).

72. MOUTH TO CAECUM TRANSIT TIME (MCTT) IS ACCELERATED AFTER ORAL FOOD ANTIGEN IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS). MG Malatesta, G Forlani, M Falcucci, AF Ciccaglione, A Castellano, N Travaglini, L Grossi, L Marzio. Gastroenterology 1996;110(4,Suppl):A712(abst).

73. MORPHOLOGICAL AND MOTOR CHANGES DURING EXPERIMENTAL COLITIS IN RATS ARE PREVENTED BY A SPECIFIC SUBSTANCE P ANTAGONIST. P di Sebastiano, L Grossi, D Angelucci, F di Mola, N Travaglini, MG Diodoro, H Friess, MW Buechler, L Marzio, P Innocenti. Gastroenterology 1996;110(4,Suppl):A896(abst).

74. MECCANISMI DI CONTROLLO DELLA MOTILITA': IL MODELLO DELLE STRIP MUSCOLARI. L Grossi, Relazione tenuta al VII Congresso Nazionale GISMAD, Perugia 19-22 Giugno 1996. Atti del Congresso GISMAD 96: 70-2.

75. IL TEMPO DI TRANSITO ORO-CECALE (TTOC) E' ACCELERATO DOPO SOMMINISTRAZIONE ORALE DI ALLERGENE ALIMENTARE NEI PAZIENTI CON SINDROME DEL COLON IRRITABILE (SCI) E PRICK TEST POSITIVO. MG Malatesta, G Forlani, M Falcucci, AF Ciccaglione, A Castellano, N Travaglini, L Grossi, L Marzio. Atti del VII Congresso GISMAD, Perugia 19-22 Giugno 1996: pag.192 (abst).

76. ALTERAZIONI CONTRATTILI DELLA MUSCOLATURA LISCIA IN CORSO DI COLITE SPERIMENTALE SONO RIDOTTE DA UN ANTAGONISTA SPECIFICO DELLA SOSTANZA P. L Grossi, P Di Sebastiano, N Travaglini, F di Mola, M Falcucci, AF Ciccaglione, P Innocenti, L Marzio. Atti del VII Congresso GISMAD, Perugia 19-22 Giugno 1996: pag 198 (abst).

77. REGISTRAZIONE DELLE 24 ORE DELLA MOTILITA' DEL PILORO IN SOGGETTI NORMALI. AF Ciccaglione, L Grossi, N Travaglini, M Falcucci, MG Malatesta, A Castellano, L Marzio. Atti del VII Congresso GISMAD, Perugia 19-22 Giugno 1996: pag 251 (abst).

78. DISTENSIONE GASTRICA NEI SOGGETTI NORMALI E NEI PAZIENTI DISPEPTICI HELICOBACTER PYLORI POSITIVI E NEGATIVI E CORRELAZIONE CON I SINTOMI. M Falcucci, MG Malatesta, AF Ciccaglione, A Castellano, N Travaglini, L Grossi, L Marzio. Atti del VII Congresso GISMAD, Perugia 19-22 Giugno 1996: pag 253 (abst).

79. EFFECT OF NITRIC OXIDE ON SPONTANEOUS CLUSTERS OF PROPAGATED MOTOR WAVES IN AN EX VIVO RABBIT INTESTINAL PREPARATION. L Grossi, M Falcucci, D Lapenna, L Marzio. Neurogastroenterology and Motility 1996; 8:201-5.

80. BENEFICIAL EFFECTS OF SR140333, A NOVEL SUBSTANCE P ANTAGONIST, IN A RAT MODEL OF EXPERIMENTAL COLITIS. P Di Sebastiano, L Grossi, D Angelucci, F Di Mola, N Travaglini, MG Diodoro, H Friess, MW Buchler, L Marzio, P Innocenti. Gut 1996; 39(Suppl 3): A246 (abst).

81. CEFTRIAXONE ASSOCIATED GALLBLADDER LITHIASIS IN CHILDREN: CASE REPORT. C De Fanis, G Sciampa, A Spadaccini, L Grossi.

The Italian Journal of Gastroenterology 1996; 28 (Suppl 2): 99(abst).

82. 24-HOUR RECORDING OF PYLORIC MOTILITY IN NORMAL HUMAN SUBJECTS. AF Ciccaglione, L Grossi, N Travaglini, M Falcucci, MG Malatesta, A Castellano, L Marzio. The Italian Journal of Gastroenterology, 1996;28,9:539(abst).

83. GASTRIC RELAXATION IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS. ROLE OF ALTERED VAGAL CONTROL ON DYSPEPTIC SYMPTOMS. M Falcucci, L Grossi, MG Malatesta, AF Ciccaglione, A Castellano, L Marzio. The Italian Journal of Gastroenterology, 1996;28,9:540(abst).

84. TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESR) AS A FACILITATING FACTOR FOR GASTRO-ESOPHAGEAL REFLUX ALSO DURING NIGHTTIME. L Grossi, AF Ciccaglione, M Falcucci, MG Malatesta, A Castellano, N Travaglini, L Marzio. The Italian Journal of Gastroenterology, 1996;28,9:542(abst).

1997

85. I RILASCIAMENTI TRANSITORI DELLO SFINTERE ESOFAGEO INFERIORE NELLA GENESI DEI REFLUSSI GASTRO-ESOFAGEI: PROSPETTIVE TERAPEUTICHE. L Marzio, L Grossi, AF Ciccaglione, F Cuccurullo. In: Argomenti di Patologia Esofagea, Springer-Verlag Italia, 1997: 29-38.

86. TRANSIENT (TLESR) AND POSTDEGLUTITIVE (PDLESR) LOWER ESOPHAGEAL SPHINCTER RELAXATIONS EVALUATED FOR 24 HOURS IN GERD PATIENTS AND NORMAL SUBJECTS. L Grossi, AF Ciccaglione, M Falcucci, MG Malatesta, A Castellano, N Travaglini, L Marzio. Gastroenterology 1997; 112,4 (Suppl):A740(abst)

87. EVIDENCE OF AN ORO-FECAL TRANSMISSION IN AN EXPERIMENTAL MURINE MODEL OF HELICOBACTER PYLORI INFECTION. L Marzio, L Cellini, L Grossi, S Di Bartolomeo, N Travaglini, D Angelucci, MG Diodoro. Gastroenterology 1997; 112,4(suppl): A212(abst).

88. PYLORIC MOTILITY RECORDED FOR 24 HOURS IN NORMAL HUMAN SUBJECTS. AF Ciccaglione, L Grossi, N Travaglini, M Falcucci, MG Malatesta, A Castellano, L Marzio. Gastroenterology 1997; 112,4 (suppl):A713(abst).

89. EFFECT OF HELICOBACTER PYLORI INFECTION ON GASTRIC SMOOTH MUSCLE CONTRACTILITY IN AN EXPERIMENTAL MURINE MODEL. L Grossi, N Travaglini, E Di Campli, T Taraborrelli, P Di Sebastiano, D Angelucci, MG Diodoro, L Marzio. Gastroenterology 1997; 112,4 (suppl):A134(abst).

90. 24-HOUR PANCOLONIC MOTILITY USING A PORTABLE ELECTRONIC PROBE IN HEALTHY SUBJECTS. AF Ciccaglione, L Grossi, F Carmosino, A Castellano, M Falcucci, MG Malatesta, L Marzio. Ital J Gastroenterol Hepatol 1997;29(suppl2): A18 (abst).

91. RELATIONSHIP BETWEEN REFLUX EPISODES AND TLESR IN NORMAL SUBJECTS AND GERD PATIENTS DURING THE 24 HOURS. L Grossi, F Carmosino, AF Ciccaglione, A Castellano, M Falcucci, MG Malatesta, L Marzio. Ital J Gastroenterol Hepatol 1997;29(suppl2): A42 (abst).

92. ROLE OF HELICOBACTER PYLORI INFECTION ON THE GENESIS AND INTENSITY OF DYSPEPTIC SYMPTOMS. L Marzio, G Cappello, F Carmosino, A Castellano, AF Ciccaglione, M Falcucci, MG Malatesta, L Grossi, A Spadaccini, G Sciampa, G Ferrini, N Semperlotti. Ital J Gastroenterol Hepatol 1997;29(suppl2): A207 (abst).

1998

93. 24-HOUR PANCOLONIC MOTILITY USING A PORTABLE ELECTRONIC PROBE IN HEALTHY SUBJECTS. L Marzio, L Grossi, AF Ciccaglione, A Castellano, M Falcucci, MG Malatesta, F Carmosino. Neurogastroenterology and Motility 1998; 10,1:85 (abst).

94. RELATIONSHIP BETWEEN ANAL CANAL DIAMETER AND PRESSURE EVALUATED SIMULTANEOUSLY BY ENDOSONOGRAPHY AND MANOMETRY IN NORMAL HUMAN SUBJECTS. L. Marzio, AF Ciccaglione, M. Falcucci, MG Malatesta, L Grossi, N Travaglini, S Guerri. Int J Colorect Dis 1998;13:21-6.

95. ANTI-HELICOBACTER PYLORIC SPECIFIC ANTIBODY IMMUNOHISTOCHEMISTRY IMPROVES THE DIAGNOSTIC ACCURACY OF HELICOBACTER PYLORI IN BIOPSY SPECIMEN FROM PATIENTS TREATED WITH TRIPLE THERAPY. L Marzio, D Angelucci, L Grossi, MG Diodoro, E Di Campli, L Cellini. Am J Gastroenterol 93,2:223-6, 1998.

96. SWALLOWING, ESOPHAGEAL AND GASTRIC MOTILITY IN NORMAL SUBJECTS AND IN PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE: A 24-HOUR PH-MANOMETRIC STUDY. L Grossi, AF Ciccaglione, N Travaglini, L Marzio. Neurogastroenterol Motil, 1998;10:115-21.

97. 24-HOUR PANCOLONIC MOTOR ACTIVITY IN HEALTHY SUBJECTS RECORDED WITH A PORTABLE ELECTRONIC DEVICE. L Marzio, L Grossi, AF Ciccaglione, F Carmosino, A Castellano, M Falcucci, MG Malatesta. Gastroenterology 1998; 114, 4(Suppl):A798 (abst).

98. ROLE OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS IN THE GENESIS OF PROXIMAL GASTRO-ESOPHAGEAL REFLUX. L. Grossi, AF Ciccaglione, G Cappello, A Castellano, MG Malatesta, L Marzio. Ital J Gastroenterol Hepatol 1998;30(Suppl.2):A109 (abst)

99. EFFECT OF GLYCERYL TRINITRATE OINTMENT (GTO) 0.2% AND 2% ON ANAL CANAL PRSSURE DURING ACUTE AND CHRONIC APPLICATION IN PATIENTS WITH ANAL FISSURE. AF Ciccaglione, L. Grossi, G Cappello, A Castellano, MG Malatesta, L Marzio. Ital J Gastroenterol Hepatol 1998;30(Suppl.2):A137 (abst)

100. HELICOBACTER PYLORI INFECTION AND DYSPEPTIC SYMPTOMS.

G Cappello, A Castellano, F Carmosino, AF Ciccaglione, MG Malatesta, L. Grossi, A Spadaccini, G Sciampa, G Ferrini, N Semperlotti, L Marzio. Ital J Gastroenterol Hepatol 1998;30(Suppl.2):A188 (abst)

101. PROXIMAL AND DISTAL GASTRIC DISTENTION IN NORMAL SUBJECTS AND H.PYLORI-POSITIVE AND -NEGATIVE DYSPEPTICS PATIENTS AND CORRELATION WITH SYMPTOMS. L Marzio, M Falcucci, L Grossi, AF Ciccaglione, MG Malatesta, A Castellano, E Ballone. Dig Dis Sci 1998;43(12):2757-63.

1999

102. SR140333, A SUBSTANCE P RECEPTOR ANTAGONIST, INFLUENCES MORPHOLOGICAL AND MOTOR CHANGES IN RAT EXPERIMENTAL COLITIS. P Di Sebastiano, L. Grossi, FF DiMola, D Angelucci, H Friess, L Marzio, P Innocenti and MW Buechler. Dig Dis Sci 1999;44(2):439-44.

103. EVIDENCE FOR AN ORAL-FAECAL TRANSMISSION OF HELICOBACTER PYLORI INFECTION IN AN EXPERIMENTAL MURINE MODEL. L Cellini, B Dainelli, D Angelucci, L. Grossi, S Di Bartolomeo, E Di Campli, L Marzio. APMIS 1999;107:477-84. I.F.: 1.016

104. TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS AND PROXIMAL GASTRO-ESOPHAGEAL REFLUX. L. Grossi, AF Ciccaglione, G Cappello, MG Malatesta, A Ferri, L Marzio. Gastroenterology 1999; vol 116, 4 (Suppl): A177 (abstr).

105. DETECTION OF HELICOBACTER PYLORI INFECTION IN THE GASTROINTESTINAL TRACT OF BALB/C EUTHYMIC MICE INFECTED BY HUMAN HELICOBACTER PYLORI AND EVIDENCE FOR TRANSMISSION. L Cellini, L Artese, S Toracchio, A Del Vito, G Ferrero, E Di Campli, L. Grossi, L Marzio. Gastroenterology 1999; vol 116, 4 (Suppl): A679 (abstr).

106. HELICOBACTER PYLORI AND DYSPEPTIC SYMPTOMS IN PATIENTS WITH NORMAL UPPER GI ENDOSCOPY. G Cappello, G Ferrini, A Spadaccini, L. Grossi, N Semperlotti, G Sciampa, L Marzio. Gastroenterology 1999; vol 116, 4 (Suppl): A132 (abstr).

107. PROLONGED RECORDING OF ANAL CANAL PRESSURE DURING ACUTE AND CHRONIC APPLICATION OF GLYCERYL TRINITRATE OINTMENT (GTO) 0.2% AND 2% IN PATIENTS WITH ANAL FISSURE. AF Ciccaglione, L. Grossi, G Cappello, MG Malatesta, A Ferri, L Marzio. Gastroenterology 1999; vol 116, 4 (Suppl): A973 (abstr).

108. SUMATRIPTAN DECREASES GASTRIC FUNDIC AREA AND REDUCES NAUSEA INDUCED BY WATER DISTENSION IN DYSPEPTIC PATIENTS. MG Malatesta, AF Ciccaglione, G Cappello, L. Grossi, A Ferri, L Marzio. Gastroenterology 1999; vol 116,4 (Suppl): A243 (abstr).

109. LAPAROSCOPIC LONGITUDINAL MIOTOMY AND HEMIFUNDOPLICATION IMPROVE ESOPHAGEAL MOTILITY PARAMETERS IN PATIENTS AFFECTED BY ACHALASIA. AF Ciccaglione, L Napolitano, L Grossi, L Marzio, P Innocenti. Gastroenterology 1999; vol 116,4 (Suppl): A1305 (abstr)

110. TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS PLAY A MINOR ROLE IN THE GENESIS OF PROXIMAL GASTRO-ESOPHAGEAL REFLUX. L. Grossi, AF Ciccaglione, G Cappello, A Ferri, MG Malatesta, L Marzio. Neurogastroenterolgy and Motility 1999;11,4:262 (abst).

111. TRASMISSIONE DI HELICOBACTER PYLORI IN UN MODELLO MURINO. L Cellini, L Marzio, G Ferrero, A Del Vito, E Di Campli, L. Grossi, S Toracchio, CMR Iodice, L Artese. GIMMOC, Vol III- C&M 2, Ott 1999

112. LA MALDIGESTIONE. L Marzio, L. Grossi. In: Manuale di Fisiopatologia Medica e Chirurgica, Il Pensiero Scientifico Editore, Ottobre 1999.

113. TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS PLAY A MINOR ROLE IN THE GENESIS OF PROXIMAL GASTRO-ESOPHAGEAL REFLUX. L. Grossi, AF Ciccaglione, G Cappello, A Ferri, MG Malatesta, L Marzio. Gut 1999; 45 (Suppl V): A84 (abst).

2000

114. EFFECT OF THE 5HT-1 AGONIST SUMATRIPTAN ON ESOPHAGEAL MOTILITY IN PATIENTS WITH UNSPECIFIED MOTOR ABNORMALITIES. L. Grossi, AF Ciccaglione, G Cappello, A Ferri, MG Malatesta, S Toracchio, L Marzio. Gastroenterology 2000; 118,4 (Suppl 2):A629 (abst)

115. EFFECT OF JOSICINE N-BUTYLBROMIDE (JNB) IN NORMAL SUBJECTS AND PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX

DISEASE: A 48-HOURS ESOPHAGEAL AND GASTRIC PH STUDY. AF Ciccaglione, L Grossi, G Cappello, MG Malatesta, A Ferri, S Toracchio, L Marzio. Gastroenterology 2000; 118,4 (Suppl 2):A15 (abst)

116. ONE HUNDRED PERCENT ERADICATION RATE WITH PERSONALIZED TRIPLE THERAPY AFETR CULTURE AND ANTIBIOGRAM IN PATIENTS WITH H.pylori INFECTION. S Toracchio, L Cellini, A Ferri, MG Malatesta, E Di Campli, G Cappello, AF Ciccaglione, L Grossi, L Marzio. Gastroenterology 2000; 118,4 (Suppl. 2):A1316 (abst).

117. OMEPRAZOLE (OME), CLARITHROMYCIN (CLA) AND TINIDAZOLE (TIN) FOR 7 DAYS VS OME, CLA AND TIN FOR 7 DAYS PLUS OME FOR 21 DAYS IN THE TREATMENT AND RECURRENCE OF ACTIVE DUODENAL ULCER WITH H. pylori INFECTION: A DOUBLE BLIND PLACEBO CONTROLLED TRIAL. L Marzio, L Grossi, L Cellini et al. Gastroenterology 2000;118, 4 (Suppl 2): A1271 (abst)

118. GASTRIC EMPTYING OF A SOLID-LIQUID MEAL MEASURED WITH ¹³C OCTANOIC ACID BREATH TEST (OBT) AND REAL-TIME ULTRASONOGRAPHY (RUS): A COMPARATIVE STUDY. G Cappello, MG Malatesta, A Ferri, AF Ciccaglione, L Grossi, L Marzio. Gastroenterology 2000;118, 4 (Suppl 2): A1164 (abst)

119. A 48-HOUR ESOPHAGEAL AND GASTRIC PH STUDY ON THE EFFECT OF HYOSCINE N-BUTYLBROMIDE (HNB) IN NORMAL SUBJECTS AND PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE. AF Ciccaglione, L Grossi, G Cappello, A Ferri, MG Malatesta, S Toracchio, L Marzio. Atti Congresso GISMAD 2000.

120. EFFECT OF SUMATRIPTAN ON ESOPHAGEAL MOTILITY IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY. L Grossi, AF Ciccaglione, G Cappello, A Ferri, MG Malatesta, S Toracchio, L Marzio. Atti Congresso GISMAD 2000.

121. GASTRIC EMPTYING OF A SOLID-LIQUID MEAL MEASURED WITH ¹³C OCTANOIC ACID BREATH TEST (OBT) AND REAL-TIME ULTRASONOGRAPHY (RUS): A COMPARATIVE STUDY. G.Cappello, MG Malatesta, F Ciccaglione, A Ferri, S Toracchio, L.Grossi, L Marzio. Atti Congresso GISMAD 2000.

122. GASTRIC EMPTYING OF A SOLID-LIQUID MEAL MEASURED WITH ¹³C OCTANOIC ACID BREATH TEST AND REAL-TIME ULTRASONOGRAPHY: A COMPARATIVE STUDY. G Cappello, MG Malatesta, A Ferri, AF Ciccaglione, S Toracchio, L Grossi, L Marzio. Am J Gastroenterol 2000;95:3097-3100.

123. DISORDINI ASPECIFICI DELLA MOTILITA' ESOFAGEA: L. Marzio, L. Grossi, AF Ciccaglione. In: Argomenti di Patologia Esofagea, 2000 Springer-Verlag Italia, vol.5:39-49.

124. ROLE OF ANTIMICROBIAL SUSCEPTIBILITY TESTING ON EFFICACY OF TRIPLE THERAPY IN *Helicobacter pylori* ERADICATION. S Toracchio, L Cellini, E Di Campli, G Cappello, MG Malatesta, A Ferri, AF Ciccaglione, L Grossi, L Marzio. Aliment Pharmacol Ther 2000;14(12):1639-43.

125. EFFECT OF SUMATRIPTAN ON ESOPHAGEAL MOTILITY IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY. L Grossi, AF Ciccaglione, A Ferri, MG Malatesta, S Toracchio, L Marzio. Digest Liver Dis 2000;32 (Suppl 2): A75 (abst).

126. ROLE OF ANTIMICROBIAL SUSCEPTIBILITY TESTING ON EFFICACY OF RTIPLE THERAPY IN *Helicobacter pylori* ERADICATION. S Toracchio, L Cellini, A Ferri, MG Malatesta, G Cappello, AF Ciccaglione, E Di Campli, L Grossi, L Marzio. Digest Liver Dis 2000;32 (Suppl 2): A89 (abst).

127. A 48-HOUR ESOPHAGEAL AND GASTRIC PH STUDY ON THE EFFECT OF HYOSCINE N-BUTYLBROMIDE (HNB) IN NORMAL SUBJECTS AND PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE. AF Ciccaglione, L Grossi, G Cappello, A Ferri, MG Malatesta, S Toracchio, L Marzio. Digest Liver Dis 2000;32 (Suppl 2): A97 (abst).

128. GASTRIC EMPTYING OF A SOLID-LIQUID MEAL MEASURED WITH 13C-OCTANOIC ACID BREATH TEST (OBT) AND REAL-TIME ULTRASONOGRAPHY (RUS): A COMPARATIVE STUDY. G Cappello, MG Malatesta, AF Ciccaglione, A Ferri, S Toracchio, L Grossi, L Marzio. Digest Liver Dis 2000;32 (Suppl 2): A160 (abst).

129. SHORT AND LONG TERM EFFICACY OF GLYCERYL TRINITRATE (GTN) OINTMENT 0.2% AND 2% ON ANAL CANAL PRESSURE IN PATIENTS WITH CHRONIC ANAL FISSURES. AF Ciccaglione, L Grossi, G.Cappello, MG Malatesta, A.Ferri, L Marzio. Dig Dis Sci 2000;45(12):2352-56.

2001

130.TRANSMISSION OF *Helicobacter pylori* IN AN ANIMAL MODEL. L Cellini, L Marzio, G Ferrero, A Del Vino, E Di Campli, L Grossi, S Toracchio, L Artese. Dig Dis Sci 2001;46(1):62-8.

131. TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS AND GASTRO-ESOPHAGEAL REFLUX EPISODES IN HEALTHY

SUBJECTS AND GERD PATIENTS DURING 24 HOURS. L. Grossi, AF Ciccaglione, N Travaglini, L Marzio. *Dig Dis Sci* 2001; 46(4): 815-21.

132. EFFECT OF HYOSCINE N-BUTYLBROMIDE ON GASTROESOPHAGEAL REFLUX IN NORMAL SUBJECTS AND PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. AF Ciccaglione, L. Grossi, G Cappello, MG Malatesta, A Ferri, S Toracchio, L Marzio. *Am J Gastroenterol* 2001;96(8):2306-11.

133. EFFECT OF GABA(B) AGONIST BACLOFEN ON GER IN NORMAL SUBJECTS AND PATIENTS WITH GERD. CiccaglioneAF, Grossi L, CapelloG, *et al.* *Gastroenterology* 2001; 120: A34.(abst)

134. TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS PLAY AN INSIGNIFICANT ROLE IN GASTRO-ESOPHAGEAL REFLUX TO THE PROXIMAL ESOPHAGUS. L. Grossi, AF Ciccaglione, L Marzio. *Neurogastroenterol Motil* 2001;13,5:503-10.

135. EFFECT OF TRAMADOL ON PATIENTS UNDERGOING COLONOSCOPY: A DOUBLE-BLIND CONTROLLED STUDY VS.PLACEBO. L. Grossi, G Cappello, AF Ciccaglione, L Marzio. *Digest Liver Dis* 2001; 33 (Suppl 1):A47 (abst)

136. EFFECT OF THE ASSOCIATION ALFA-2b INTERFERON AND RIBAVIRIN IN A GROUP OF "NAIVE" PATIENTS HCV-POSITIVE PATIENTS. L. Grossi, L Marzio. *Digest Liver Dis* 2001; 33 (Suppl 1):A92 (abst)

Altri abstracts gastroenterology 2001?

2002.

137. ATTIVITA' MOTORIA ESOFAGEA E GASTRICA INDOTTA DAL SUMATRIPTAN COME POSSIBILE PARTE DEI COMPLESSI MOTORI MIGRANTI INTERDIGESTIVI. L. Grossi, L Marzio. *Atti congresso Nazionale GISMAD (Marina di Ostuni 29-31 Maggio 2002):* 60 (abst)

138. 5-HT₁-RECEPTOR AGONIST SUMATRIPTAN MODIFIES GASTRIC SIZE AFTER 500 ML OF WATER IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS. MG Malatesta, E Fascetti, AF Ciccaglione, G Cappello, L. Grossi, A Ferri, L Marzio. *Dig Dis Sci* 2002;47,11:2591-5

2003.

139. EFFECT OF THE 5-HT₁ AGONIST SUMATRIPTAN ON ESOPHAGEAL MOTOR PATTERN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY. L. Grossi, AF Ciccaglione, L Marzio. *Neurogastroenterology and motility*, 2003;15,1:9-14.

140. HIGH CONSUMPTION OF RED PEPPER REDUCES THE INCIDENCE OF INEFFECTIVE ESOPHAGEAL MOTILITY IN GERD PATIENTS. L. Grossi, G. Cappello, A. Ferri, L. Marzio. *Dig Liv Dis* 2003; 35,4: P140 (abst)

141. HIGH CONSUMPTION OF RED CHILLY PEPPER REDUCES THE INCIDENCE OF INEFFECTIVE ESOPHAGEAL MOTILITY IN GERD PATIENTS. L. Grossi, G. Cappello, A. Ferri, L. Marzio. *Acts of 19th Intl Symposium of GI motility, Barcelona, Oct 2003:* page 28 (abst)

2004.

142. PROLONGED EFFECT OF BACLOFEN ON ESOPHAGEAL MOTILITY: A 48-HOUR MANOMETRIC STUDY IN HEALTHY SUBJECTS. L. Grossi, G. Cappello, M. Spezzaferro, L. Marzio. *Dig Liv Dis* 2004;36, Suppl.2:S160(abst)

143. ACUTE EFFECT OF CAPSAICIN ON ESOPHAGEAL MOTOR ACTIVITY IN GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY. L. Grossi, G. Cappello, M. Spezzaferro, L. Marzio. *Dig Liv Dis* 2004;36, Suppl.2:S160(abst)

144. PROLONGED EFFECT OF BACLOFEN ON ESOPHAGEAL MOTOR ACTIVITY: A 48-HOUR MANOMETRIC STUDY IN HEALTHY SUBJECTS. L. Grossi, G. Cappello, M. Spezzaferro, L. Marzio. *Digestive Disease Week, New Orleans 2004 (abst)*

145. PREMEDICATION WITH TRAMADOL IN PATIENTS UNDERGOING COLONOSCOPY: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED STUDY. L. Grossi, G Cappello, L Marzio. *Dig Dis Sci* 2004;49,10:1641-5

2005.

146. THE EFFECT OF ONDANSETRON ON THE GASTRIC EMPTYING OF A SOLID-LIQUID MEAL MEASURED WITH C13 OCTANOIC BREATH TEST. G Cappello, L. Grossi, S. Capodicasa, M. Spezzaferro, A. Barchiesi, L. Marzio. *Dig Liv Dis*2005; 37,Suppl 1: S15(abst).

147. EFFECT OF AN ACUTE ADMINISTRATION OF CAPSAICIN ON ESOPHAGEAL MOTILITY IN PATIENTS WITH SCLERODERMA. L. Grossi, G Cappello, S. Capodicasa, M. Spezzaferro, A. Barchiesi, G De Berardinis, L. Marzio. *Dig Liv Dis*2005; 37,Suppl 1: S77(abst).

148. RESISTANCE AND THERAPEUTIC UTILITY OF FLUOROCHINOLONES IN HUMAN H.PYLORI INFECTION. S. Capodicasa, D Coraggio, G

Cappello, L. Grossi, M. Spezzaferro, L. Marzio. Dig Liv Dis 2005; 37, Suppl 1: S77(abst)

149. EFFECT OF AN ACUTE INTRALUMINAL ADMINISTRATION OF CAPSAICIN ON ESOPHAGEAL MOTILITY IN PATIENTS AFFECTED BY SCLERODERMA. L. Grossi, G Cappello, S Capodicasa, G De Berardinis, M Spezzaferro, L Marzio. Gastroenterology 2005; 128, 4 (Suppl 2): M1869(abst)

150. RESISTANCE AND THERAPEUTIC UTILITY OF FLUOROQUINOLONES IN HUMAN H.PYLORI INFECTION. S Capodicasa, D Coraggio, G Cappello, M Spezzaferro, L. Grossi, L Marzio. Gastroenterology 2005; 128, 4 (Suppl 2): T946(abst)

151. FIRST AND SECOND LINE THERAPY OF H.pylori INFECTION WITH LEVOFLOXACIN, AMOXICILLIN AND ESOMEPRAZOLE WITH AND WITHOUT SUSCEPTIBILITY TEST. L Marzio, D Coraggio, S Capodicasa, L. Grossi, G Cappello. Can J Gastroenterol 2005; 19, Suppl C: R 0223(abst; Atti World Congress of Gastroenterology, Montreal, Set 2005).

2006

152. EFFICACIA E SICUREZZA DEL RITRATTAMENTO CON INFLIXIMAB IN UN PAZIENTE AFFETTO DA MORBO DI CROHN. L. Grossi, M Spezzaferro, L Marzio. IMID CASE REPORT 2006; Editore: Mediserve Communications, Vol I: pag 101.

153. CHANGE IN PRIMARY AND SECONDARY ANTIBIOTIC RESISTANCE OF H.PYLORI STRAINS ISOLATED FROM DYSPEPTIC PATIENTS DURING THE YEARS 2003-2005. D Coraggio, G De Berardinis, M Spezzaferro, L. Grossi, L Marzio. Dig Liv Dis 2006, 38, Suppl 1: S8(abst)

154. EFFECT OF PHYSIATRIC APPROACH ON ESOPHAGEAL MOTOR PATTERN IN PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. L. Grossi, G Lombardozi, D Cammarata, M Spezzaferro, D Coraggio, S Ferr, L Marzio. Dig Liv Dis 2006, 38, Suppl 1: S64(abst)

155. MAINTENANCE OF REMISSION USING LONG-TERM TREATMENT WITH INFLIXIMAB IN PATIENTS WITH CROHN'S DISEASE: AN EXPERIENCE UP TO THREE YEARS. L. Grossi, G De Berardinis, M Spezzaferro, D Coraggio, L Marzio. Dig Liv Dis 2006, 38, Suppl 1: S199(abst)

156. PEPPERMINT OIL (MINTOIL) IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME. A PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED TRIAL. G Cappello, D Coraggio, G De Berardinis, M Spezzaferro, L. Grossi, L Marzio. Dig Liv Dis 2006, 38, Suppl 1: S202(abst)

157. PEPPERMINT OIL (MINTOIL) IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME. A PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED TRIAL. G Cappello, M Spezzaferro, D Coraggio, L. Grossi, L Marzio. Gastroenterology 2006 (DDW Los Angeles 2006)

158. DETECTION OF HELICOBACTER PYLORI IN ESOPHAGUS AND SALIVA IN HUMANS. L Cellini, R Grande, D Coraggio, L. Grossi, L Marzio. Gastroenterology 2006 (DDW Los Angeles 2006)

159. EFFECT OF AN ACUTE INTRALUMINAL ADMINISTRATION OF CAPSAICIN ON OESOPHAGEAL MOTOR PATTERN IN GORD PATIENTS WITH INEFFECTIVE OESOPHAGAL MOTILITY. L. Grossi, G Cappello, L Marzio. Neurogastroenterol Motil 2006; 18,8: 632-6.

160. ROLE OF THE PRELIMINARY SUSCEPTIBILITY TESTING FOR INITIAL AND AFTER FAILED THERAPY OF HELICOBACTER PYLORI INFECTION WITH LEVOFLOXACIN, AMOXICILLIN, AND ESOMEPRAZOLE. L Marzio, D Coraggio, S Capodicasa, L. Grossi, G Cappello. Helicobacter 2006; 11:237-42.

161. EFFECT OF A PHYSIATRIC APPROACH ON THE ESOPHAGEAL MOTILITY IN GERD PATIENTS. L. Grossi, G Lombardozi, M Spezzaferro, D Coraggio, L Marzio. J Clin Gastroenterol 2006;40, Suppl 4: S202-3(abst)

2007

162. DOLORE TORACICO. L Marzio, L. Grossi. In: Manuale di Gastroenterologia, Ed. 2007-2009, Editrice Gastroenterologica Italiana: pag 24-29.

163. INCREASE IN HEART RATE DURING ESOPHAGEAL ACID REFLUX IN PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD). L. Marzio; V. Torella; M. Spezzaferro; F. M. Sacco; F. Sozio; L. Grossi. Gastroenterology 2007;132, 4 (Suppl 2): T1158 (abstract DDW 2007).

164. EFFECT OF THE GABA ANALOGUE PREGABALIN ON 24-HOUR OESOPHAGEAL PH-METRY IN HEALTHY SUBJECTS AND IN PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE: A DOUBLE-BLIND RANDOMIZED STUDY VERSUS PLACEBO. L. Grossi, M Spezzaferro, F. Sacco, F Sozio, V Torella, L Marzio. Gastroenterology 2007;132, 4 (Suppl 2): T1193 (abstract DDW 2007).

165. PEPPERMINT OIL (MINTOIL^(R)) IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A PROSPECTIVE DOUBLE BLIND

PLACEBO-CONTROLLED RANDOMIZED TRIAL. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Dig Liver Dis. 2007 Jun;39(6):530-536.

166. EFFECT OF THE GABA ANALOGUE PREGABALIN ON 24-HOUR OESOPHAGEAL PH-METRY IN HEALTHY SUBJECTS AND IN PATIENTS WITH GASTRO-OESOPHAGEAL REFLUX DISEASE: A DOUBLE-BLIND RANDOMIZED STUDY VERSUS PLACEBO. L. Grossi, M Spezzaferro, F. Sacco, F Sozio, V Torella, L Marzio.
Dig Liv Dis 2007;39,Suppl2: S143(abst)

167. RISPOSTA CLINICA E GUARIGIONE DELLA MUCOSA DOPO 4 ANNI DI TERAPIA CON INFLIXIMAB IN UN PAZIENTE CON MALATTIA DI CROHN ILEALE STEROIDO-RESISTENTE. L. Grossi. IMID Journal 2007, Editore: Mediserve Communications;1,3: 29-31.

2008.

168. EFFECT OF THE 5-HT₃ RECEPTOR ANTAGONIST, ONDANSETRON, ON GASTRIC SIZE IN DYSPEPTIC PATIENTS WITH IMPAIRED GASTRIC ACCOMODATION L.Marzio, G. Cappello, L. Grossi, L. Manzoli. Dig Liv Dis 2008;40;188-93.

169. EFFECT OF THREE DIFFERENT REGIMENS WITH ESOMEPRAZOLE, AMOXICILLIN AND MOXIFLOXACIN IN THE TREATMENT OF PRIMARY H.PYLORI INFECTION. F. Sacco, M.Spezzaferro, M. Serio, M. Amitrano, B. Cerasa, L. Grossi, L. Marzio. Dig Liv Dis 2008;40, Suppl1: S86

170. H.PYLORI ISOLATES FROM PROXIMAL AND DISTAL STOMACH OF PATIENTS WITH H.PYLORI INFECTION EXHIBIT RESISTANCE AND SENSITIVITY TO THE SAME ANTIBIOTIC. M. Amitrano, M.Spezzaferro, F. Sacco, M. Serio, , B. Cerasa, L. Grossi, L. Marzio. Dig Liv Dis 2008;40, Suppl1: S39

171. PROLONGED SCHEDULED THERAPY WITH INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: EVALUATION OF CLINICAL REMISSION AND MUCOSAL HEALING. L. Grossi, M.Spezzaferro, F. Sacco, M. Serio, M. Amitrano, B. Cerasa, L. Marzio. Dig Liv Dis 2008;40, Suppl1: S128.

172. EFFECT OF THREE DIFFERENT REGIMENS WITH ESOMEPRAZOLE, AMOXICILLIN AND MOXIFLOXACIN IN THE TREATMENT OF PRIMARY H.PYLORI INFECTION. F Sacco, M Spezzaferro, M. Serio, M. Amitrano, B. Cerasa, L. Grossi, L. Marzio. Gastroenterology 2008; 134, Suppl 1:140(abstract DDW).

173. H.PYLORI ISOLATES FROM PROXIMAL AND DISTAL STOMACH OF PATIENTS WITH H.PYLORI INFECTION EXHIBIT RESISTANCE AND SENSITIVITY TO THE SAME ANTIBIOTIC. M. Amitrano, M. Spezzaferro, F Sacco, M. Serio, B. Cerasa, L. Grossi, L Marzio. Gastroenterology 2008; 134, Suppl 1:M1087(abstract DDW).

174. EFFECT OF BACLOFEN ON ESOPHAGEAL MOTILITY AND TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS IN GERD PATIENTS: A 48-HOUR MANOMETRIC STUDY. L. Grossi, M. Spezzaferro, L. F. Sacco, L. Marzio. Neurogastroenterol Motil 2008;20:760-66.

2009.

175. EFFECT OF ALPHA-GALACTOSIDASE ON 24-HOUR ESOPHAGEAL pH-PROFILE IN PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE. L.Grossi, L.F.Sacco, M.Serio, B. Cerasa, L. Marzio. Dig Liv Dis 2009;41(Supp):S49 (abst).

176. ULTRASOUND CONTRAST ENHANCED EXAMINATION OF THE THICKENED BOWEL WALL AS AN INDEX OF INFLAMMATION IN PATIENTS WITH CROHN'S DISEASE. A. Di Tullio, M. Spezzaferro, L.F. Sacco, M.Serio, B. Cerasa, L. Grossi, L. Marzio. Dig Liv Dis 2009;41(Supp):S126 (abst).

177. AIR VOLUME IN THE GUT IN NORMAL HUMAN SUBJECTS MEASURED BY COMPUTED TOMOGRAPHY: DETERMINATION OF NORMAL VALUES AND VALIDITY OF THE RESULTS. M.E. Serio, L. Migliorato, M. Spezzaferro, L.F. Sacco, B. Cerasa, L. Grossi, L. Marzio. Dig Liv Dis 2009;41(Supp):S164 (abst)

178. TERAPIA CON INFLIXIMAB E GRAVIDANZA IN PAZIENTI CON MALATTIA INFIAMMATORIA CRONICA INTESTINALE. L. Grossi. Immunonews 2009; vol 1, 1:9-11.

179. EFFECT OF ALPHA-GALACTOSIDASE ON 24-HOUR ESOPHAGEAL pH-PROFILE IN PATIENTS WITH GASTRO-ESOPHAGEAL REFLUX DISEASE. L.Grossi, L.F.Sacco, M.Serio, B. Cerasa, A Di Tullio, L. Marzio. Digestive Disease Week 2009, Chicago: M1881 (abst)

180. AIR VOLUME IN THE GUT IN NORMAL HUMAN SUBJECTS MEASURED BY COMPUTED TOMOGRAPHY: DETERMINATION OF NORMAL VALUES AND VALIDATION OF THE TECHNIQUE. M.E. Serio, L. Migliorato, M. Spezzaferro, L.F. Sacco, B. Cerasa, L. Grossi, L. Marzio. Digestive Disease Week 2009, Chicago: W1056 (abst)

181. ULTRASOUND CONTRAST ENHANCED EXAMINATION OF THE THICKENED BOWEL WALL AS AN INDEX OF INFLAMMATION IN PATIENTS WITH CROHN'S DISEASE. A. Di Tullio, M. Spezzaferro, L.F. Sacco, M.Serio, B. Cerasa, L. Grossi, L. Marzio. . Digestive Disease Week 2009, Chicago: W1171 (abst)

182. GRAVIDANZA IN UNA PAZIENTE AFFETTA DA RETTOCOLITE ULCEROSA IN TERAPIA CON INFLIXIMAB: CASO CLINICO. L. Grossi, B. Cerasa, L.Marzio, L.F. Sacco, M. Serio. IMID Case Reports, vol IX, 2009. Ed. MEDISERVE: 61-63

2010.

183. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Sacco F, Spezzaferro M, Amitrano M, Grossi L, Manzoli L, Marzio L. Dig Liver Dis. 2010;42,2:110-4.

184. A "REAL LIVE" EXPERIENCE OF INFLIXIMAB USE FOR CROHN'S DISEASE IN SOUTHERN ITALY. M. Lo Presti, A. Privitera, M. Cappello, A. Lauria, M. Principi, N. Della Valle, L. Grossi, W. Fries. Dig Liv Dis 2010, 42 Supp:S127

185. LACTOSE MALABSORPTION (LM) AND IRRITABLE BOWEL SYNDROME (IBS): INCIDENCE AND EVALUATION OF SYMPTOMS. M. Serio, L.F. Sacco, A.M. DiTullio, L. Grossi, L. Marzio. Dig Liv Dis 2010, 42 Supp:S177

186. GIOVANE PAZIENTE CON PRIMO ATTACCO DI RETTOCOLITE ULCEROSA. Grossi L. In: Scenari Clinici; Edito da Medica Editoria e Diffusione Scientifica, 2010: 4-6.

187. GASTRIC AND GALLBLADDER EMPTYING AFTER STANDARD SOLID MEAL IN NORMAL CONTROLS, PATIENTS WITH "MOTILITY-LIKE" DYSPEPSIA AND EFFECT OF DOMPERIDONE. L. Marzio, M. Pagliaro, L.F. Sacco, M. Serio, A. Di Tullio, L. Grossi. Digestive Disease Week 2010, New Orleans, USA: 384(abst)

188. LACTOSE MALABSORPTION (LM) AND IRRITABLE BOWEL SYNDROME (IBS): INCIDENCE AND EVALUATION OF SYMPTOMS. M. Serio, L.F. Sacco, A.M. DiTullio, L. Grossi, L. Marzio. Digestive Disease Week 2010, New Orleans, USA:769(abst)

189. DOLORE TORACICO. L. Marzio, L. Grossi. In: Manuale di Gastroenterologia UNIGASTRO, Edizione 2010-12. Editrice Gastroenterologica Italiana: 14-19.

190. EFFICACY AND SAFETY OF LONG-TERM INFLIXIMAB USE FOR CROHN'S DISEASE IN SOUTHERN ITALY. A.Privitera, M.A. LoPresti, M. Mastronardi, M. Cappello, L. Grossi, A. Lauria, N. Della Valle, M. Principi, N. Buccianti, G. Di matteo, W. Fries. Gut 2010;59(Suppl III): A194

2011

191. LONG-TERM INFLIXIMAB TREATMENT IN CROHN'S DISEASE – EFFICACY AND SAFETY. W.Fries, AC Privitera, A. Belvedere, M. Mastronardi, M. Cappello, L. Grossi, A. Lauria, M. principi, N. della Valle, N. Buccianti, Journal of Crohn's and Colitis, 2011; 5,1:S120 (abst)

192. THERAPY-RELATED ADVERSE EVENTS IN CROHN'S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY. W Fries, M. Mastronardi, M. Cappello, L. Grossi, G. Costantino, F. Furfaro, A. Belvedere, A. Lauria, M. Principi, N. della Valle, N. Buccianti, A.Alibrandi, AC Privitera. Journal of Crohn's and Colitis, 2011; 5,1:S138 (abst)

193. EFFICACY AND SAFETY OF INFLIXIMAB IN THE LONG-TERM IN CROHN'S DISEASE. W. Fries, A.C. Privitera, M.A. LoPresti, M. Mastronardi, M. Cappello, L. Grossi, A. Lauria, M. Principi, N. Della Valle, N. Buccianti. Dig Liv Dis 2011, 43, Suppl 3: S134 (abst).

194. EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: EVALUATION USING HIGH RESOLUTION MANOMETRY. L. Grossi, M. Serio, A.M. DiTullio, M. Pagliaro, C. Salvatore, R. Tavani, L. Marzio. Dig Liv Dis 2011, 43, Suppl 3: S193 (abst).

195. EVALUATION OF FIBROSIS AND INTRAPARENCHIMAL BLOOD FLOW IN CIRRHOTIC PATIENTS, CHRONIC ACTIVE HEPATITIS AND NORMAL CONTROLS THROUGH FIBROSCAN AND ULTRASOUND ENHANCED CONTRAST MEDIA. S. Cocciolillo, F. Sozio, M. serio, A.M. di Tullio, M. Pagliaro, L. Grossi, G. Parruti, L. Marzio. Dig Liv Dis 2011, 43, Suppl 3: S236 (abst).

196. THERAPY- RELATED ADVERS EVENTS IN CROHN'S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY. W. fries, M. Mastronardi, M. Cappello, L. Grossi, A. Lauria, M. Principi, N. Della Valle, N. Buccianti, G. Costantino, F. Furfaro, A. Alibrandi, A.C. Privitera. Dig Liv Dis 2011, 43, Suppl 3: S252 (abst).

197. EVALUATION OF FIBROSIS AND INTRAPARENCHIMAL BLOOD FLOW IN CIRRHOTIC PATIENTS, CHRONIC ACTIVE HEPATITIS AND NORMAL CONTROLS THROUGH FIBROSCAN AND ULTRASOUND ENHANCED CONTRAST MEDIA. S. Cocciolillo, F. Sozio, M. Serio, M. Pagliaro, L. Grossi, G. Parruti, L. Marzio. Digestive Disease Week, Chicago 7-10 May 2011: Su1310(abst)

198. HIGH RESOLUTION MANOMETRY EVALUATION OF THE EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN PATIENTS AFFECTED BY INEFFECTIVE ESOPHAGEAL MOTILITY. L. Grossi, M. Serio, A.M. Di Tullio, M. Pagliaro, C. Salvatore, L. Marzio. Digestive Disease Week, Chicago 7-10 May 2011: Mo1209(abst)

199. HELICOBACTER PYLORI ISOLATES FROM PROXIMAL AND DISTAL STOMACH OF PATIENTS NEVER TREATED AND ALREADY TREATED SHOW GENETIC VARIABILITY AND DISCORDANT ANTIBIOTIC RESISTANCE. Marzio L, Cellini L, Amitrano M, Grande R, Serio M, Cappello G, Grossi L. Eur J Gastroenterol Hepatol. 2011 Jun;23(6):467-72.

2012.

200. RELATIONSHIP BETWEEN HELICOBACTER PYLORI INFECTION AND GERD SYMPTOMS. L. Grossi, A.M. DiTullio, M. Pagliaro, R. Tavani, S. Cocciolillo, A.F. Ciccaglione, L. Marzio. Dig Liv Dis 2012; vol 4 Suppl2: S152 (abst)

201. MOXIFLOXACIN CONTAINING TRIPLE THERAPY VS MOXIFLOXACIN AND BISMUTH-CONTAINING QUADRUPLE THERAPY FOR FIRST-LINE THERAPY OF HELICOBACTER PYLORI (H.PYLORI) INFECTION. A.F. Ciccaglione, L. Cellini, L. Grossi, A.M. DiTullio, M. Pagliaro, R. Tavani, S. Cocciolillo, L. Marzio. Dig Liv Dis 2012; vol 4 Suppl2: S208 (abst)

202. EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN PATIENTS WITH SCLERODERMA: EVALUATION USING HIGH RESOLUTION MANOMETRY. L. Grossi, A.M. DiTullio, M. Pagliaro, R. Tavani, S. Cocciolillo, A.F. Ciccaglione, L. Marzio. Dig Liv Dis 2012; vol 4 Suppl2: S218 (abst)

203. MOXIFLOXACIN CONTAINING TRIPLE THERAPY VS. MOXIFLOXACIN AND BISMUTH-CONTAINING QUADRUPLE THERAPY FOR FIRST-LINE TREATMENT OF HELICOBACTER PYLORI (H. PYLORI) INFECTION. A. F. Ciccaglione, L. Cellini, L. Grossi, A.M. Di Tullio, M. Pagliaro, R. Tavani, S. Cocciolillo, L. Marzio. Digestive Disease Week, San Diego 19-22 May 2012: Gastroenterology 2012, Vol. 142, Issue 5, Suppl 1: S-482 Su1691 (abst)

204. QUADRUPLE THERAPY WITH MOXIFLOXACIN AND BISMUTH FOR FIRST-LINE TREATMENT OF HELICOBACTER PYLORI. AF Ciccaglione, L Cellini, L. Grossi, L Marzio. World J Gastroenterol 2012;18(32):4386-90.

205. CAN HELICOBACTER PYLORI INFECTION HAVE A ROLE ON CLINICAL APPEARANCE OF GERD? L. Grossi, A.M. Di Tullio, M. Pagliaro, R. Tavani, S. Cocciolillo, O. Ferri, A.F. Ciccaglione, L. Marzio. Gut 2012;61(Suppl.3): A327(abst)

2013.

206. SAFETY OF INFLIXIMAB INFUSIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A 10 YEARS REAL-LIFE EXPERIENCE FROM A SINGLE CENTRE. L. Grossi, A.M. Di Tullio, M. Pagliaro, R. Tavani, S. Cocciolillo, O. Ferri, A.F. Ciccaglione, L. Marzio. Dig Liv Dis 2013; 45,2: S104 (abst)

207. ROLE OF WEAKLY ACIDIC REFLUXES IN THE ATYPICAL SYMPTOMS OF GERD. A pH-IMPEDANCE STUDY PERFORMED OFF-PPI THERAPY. L. Grossi, A.M. Di Tullio, M. Pagliaro, R. Tavani, S. Cocciolillo, A.F. Ciccaglione, L. Marzio. Dig Liv Dis 2013; 45,2: S111 (abst)

208. INCIDENCE OF LATENT TUBERCULOSIS INFECTION IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE. DATA ON CROHN'S DISEASE AND ULCERATIVE COLITIS FROM A SINGLE CENTRE. M. Pagliaro, A.M. Di Tullio, R. Tavani, S. Cocciolillo, F. Sozio, A. Sepe, L. Grossi, G. Parruti, L. Marzio. Dig Liv Dis 2013; 45,2: S148 (abst)

209. EVALUATION OF LIVER BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND AND FIBROSIS BY FIBROSCAN IN PATIENTS WITH NON ALCOHOLIC STEATO-HEPATITIS (NASH) AND NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND COMPARISON WITH NORMAL CONTROLS. S. Cocciolillo, R. Tavani, A. M. Di Tullio, M. Pagliaro, A.F. Ciccaglione, A. Sepe, M. Di Berardino, L. Grossi, L. Marzio. Dig Liv Dis 2013; 45,2: S216 (abst)

210. EVALUATION OF INTRA PARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSIS BY FIBROSCAN IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON ALCOHOLIC STEATOHEPATITIS (NASH) AND COMPARISON WITH NORMAL CONTROLS. S. Cocciolillo, F. Sozio, A.M. Di Tullio, M. Pagliaro, L. Grossi, A.F. Ciccaglione, R. Tavani, M. Di Berardino, G. Parruti, L. Marzio. Gastroenterology 2013;144, 5(Suppl. 1): S77-S78. (abst)

211. LATENT TUBERCULOSIS AND IBD: IS THE INCIDENCE OF THE INFECTION DIFFERENT BETWEEN CROHN'S DISEASE AND ULCERATIVE COLITIS? EXPERIENCE FROM A SINGLE CENTRE OF THE MIDDLE ITALY. M. Pagliaro, L. Grossi, A.M. Di Tullio, R. Tavani, S. Cocciolillo, F. Sozio, A.F. Ciccaglione, G. Parruti, L. Marzio. Gastroenterology 2013;144, 5(Suppl. 1):S413

212. INFLIXIMAB IS EFFECTIVE AND SAFE FOR BOTH STEROID-RESISTANT AND STEROID-DEPENDENT ULCERATIVE COLITIS: A "REAL-LIFE" EXPERIENCE IN A LARGE MULTICENTER SERIES. M. Cappello, M. Mazza, G. Costantino, W. Fries, A.C. Privitera, M.

Mastronardi, F. Bossa, F. Castiglione, A. Rispo, A. Lauria, N. Bucciante, R. Marasco, L. Grossi, P.L. Almasio. United European Gastroenterology Journal 2013;1, A1:A34 (abst) OP 116.

213. INFLIXIMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS: RESULTS OF A LARGE MULTICENTER ITALIAN SURVEY. M. Cappello, M. Mazza, G. Costantino, W. Fries, A.C. Privitera, M. Mastronardi, F. Bossa, A. Rispo, F. Castiglione, A. Lauria, N. Bucciante, R. Marasco, L. Grossi, M.B. Principi. Journal of Crohn's and Colitis, Feb 2014, 8 Suppl.1: S252(abst)

2014.

214. INFLIXIMAB IN STEROID-DEPENDENT ULCERATIVE COLITIS: LACK OF PREDICTIVE FACTORS FOR RESPONSE IN A LARGE MULTICENTER SERIES. M. Cappello, M. Mazza, G. Costantino, W. Fries, A.C. Privitera, M. Mastronardi, F. Bossa, A. Rispo, F. Castiglione, A. Lauria, N. Bucciante, R. Marasco, L. Grossi, M.B. Principi, P.L. Almasio. Dig Liv Dis 2014, 46, Suppl. 2: S78(abst).

215. RIFABUTIN CONTAINING TRIPLE THERAPY VS. RIFABUTIN AND BISMUTH-CONTAINING QUADRUPLE THERAPY FOR THIRD-LINE TREATMENT OF HELICOBACTER PYLORI (H.PYLORI) INFECTION. R. Tavani, A.F. Ciccaglione, L. Cellini, L. Grossi, A.M. Di Tullio, M. Pagliaro, S. Cocciolillo, A. Sepe, M. Di Berardino, L. Marzio. Dig Liv Dis 2014, 46, Suppl. 2: S111(abst).

216. OBSERVATIONAL TRIAL THROUGH CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSCAN OF PATIENTS WITH NON ALCOHOLIC STEATO-HEPATITIS (NASH) AND DYSLIPIDEMIA (TYPE 2A OR 2B) UNDERGOING SIMVASTATIN TREATMENT. S. Cocciolillo, A.M. Di Tullio, M. Pagliaro, R. Tavani, M. Di Berardino, A. Sepe, A. Ladisa, A.F. Ciccaglione, L. Grossi, G. Parruti, L. Marzio. Dig Liv Dis 2014, 46, Suppl. 2: S117(abst).

217. EVALUATION OF LIVER BLOOD FLOW AND FIBROSIS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CIRRHOSIS IN COMPARISON WITH NORMAL CONTROLS THROUGH CONTRAST ENHANCED ULTRASOUND(CEUS) AND FIBROSCAN. S. Cocciolillo, A.M. Di Tullio, M. Pagliaro, R. Tavani, M. Di Berardino, A. Sepe, L. Grossi, A.F. Ciccaglione G. Parruti, L. Marzio. Dig Liv Dis 2014, 46, Suppl. 2: S118(abst).

218. ROLE OF PRUCALOPRIDE IN THE SETTING-UP OF PILLCAM COLON-CAPSULE ENDOSCOPY (CCE). EXPERIENCEFROM A SINGLE CENTRE. A. Sepe, A.M. Di Tullio, M. Pagliaro, R. Tavani, S. Cocciolillo, M. Di Berardino, A.F. Ciccaglione, L. Grossi, L. Marzio. Dig Liv Dis 2014, 46, Suppl. 2: S130(abst).

219. ROLE OF PRUCALOPRIDE (RESOLOR) IN THE SETTING-UP OF PILLCAM COLON-CAPSULE ENDOSCOPY (CCE). EXPERIENCEFROM A SINGLE CENTRE. A. Sepe, L. Grossi, A.F. Ciccaglione, A.M. Di Tullio, M. Pagliaro, R. Tavani, S. Cocciolillo, M. Di Berardino, L. Marzio. Gastroenterology 2014, Vol. 146, Issue 5 Suppl. 1, S-766

2015.

220. MAINTENANCE OF REMISSION AFTER PROLONGED THERAPY WITH INFLIXIMAB: A "REAL-LIFE" EXPERIENCE FROM A SINGLE ITALIAN CENTRE IN PATIENTS AFFECTED BY CROHN'S DISEASE AND ULCERATIVE COLITIS. L. Grossi, M. Pagliaro, A.M. Di Tullio, R. Tavani, S. Cocciolillo, M. Di Berardino, A. Sepe. A.F. Ciccaglione, L. Marzio. Journal of Crohn's and Colitis 2015, vol 9/S1:S211 (abst)

221. A TRIPLE AND QUADRUPLE THERAPY WITH DOXYCYCLINE AND BISMUTH FOR FIRST.LINE TREATMENT OF *Helicobacter pylori* INFECTION: A PILOT SUDY. Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L. Helicobacter 2015; 20,5:390-6.

222. SAFETY OF INFLIXIMAB(IFX) ONE-HOUR INFUSION IN INFLAMMATORY BOWEL DISEASE(IBD): A MULTICENTER STUDY FROM SOUTHERN ITALY. M. Cappello, M. Mazza, G. Costantino, A.C. Privitera, F. Bossa, A. Lauria, L. Grossi, M.B. Principi, N. Della Valle. Dig Liv Dis 2015; 47(Suppl. 2): e131(abst)

223. MAINTENANCE OF REMISSION AFTER PROLONGED THERAPY WITH INFLIXIMAB: A "REAL-LIFE" EXPERIENCE FROM A SINGLE ITALIAN CENTRE IN PATIENTS AFFECTED BY CROHN'S DISEASE AND ULCERATIVE COLITIS. M. Pagliaro, L. Grossi, A.M. Di Tullio, R. tavani, S. Cocciolillo, A. Sepe, M. Di Berardino, A.F. Ciccaglione, L. Marzio. Dig Liv Dis 2015; 47(Suppl. 2): e181(abst)

224. EVALUATION THROUGH FIBROSCAN AND CONTRAST ENHANCED ULTRASOUND(CEUS) OF LIVER STIFFNESS AND LIVER PARENCHYMA BLOOD FLOW IN NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD), CHRONIC HEPATITIS C(CHC) WITHOUT CHRRHOSIS VS NORMAL CONTROLS. S. Cocciolillo, A.M. Di Tullio, M. Pagliaro, R. Tavani, M. Di Berardino, A. Sepe, A.F. Ciccagliene, L. Grossi, G. Parruti, L. Marzio. Dig Liv Dis 2015; 47(Suppl. 2): e188(abst)

225. ULTRASOUND(US) GRADED HEPATOSTEATOSIS ASSESSMENT THROUGH CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSCAN IN NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD). S. Cocciolillo, A.M. Di Tullio, M. Pagliaro, R. Tavani, M. Di Berardino, A. Sepe, A.F. Ciccagliene, L. Grossi, G. Parruti, L. Marzio. Dig Liv Dis 2015; 47(Suppl. 2): e189(abst)

226. EVALUATION THROUGH FIBROSCAN AND CONTRAST ENHANCED ULTRASOUND (CEUS) OF LIVER STIFFNESS AND LIVER PARENCHYMA BLOOD FLOW IN NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD), CHRONIC HEPATITIS C (CHC) WITHOUT CIRRHOSIS VS NORMAL CONTROLS. S. Cocciolillo, A. M. Di Tullio, M. Pagliaro, R. Tavani, M. di Berardino, A. Sepe, A. F. Ciccaglione, L. Grossi, G Parruti, L. Marzio. Gastroenterology 2015, Vol. 148, Issue 4, Suppl 1 S-170–S-171

227. PRUCALOPRIDE INCREASES BASAL LES TONE IN PATIENTS WITH ESOPHAGEAL MOTILITY DISORDERS. A. Pitocco, L. Grossi, M. Di Berardino, A. F. Ciccaglione, L. Marzio. UEG Journal October 2015 : Volume 3 : Supplement 1: A477.

228. TYPICAL AND ATYPICAL SYMPTOMS OF GASTRO ESOPHAGEAL REFLUX DISEASE: DOES *Helicobacter pylori* MATTER? L. Grossi, A.F. Ciccaglione, L. Marzio. World J Gastrointest Pharmacol Ther 2015; 6(4):238-43

2016.

229. IN VITRO ANTIMICROBIAL SUSCEPTIBILITY OF HELICOBACTER PYLORI TO NINE ANTIBIOTICS CURRENTLY USED IN CENTRAL ITALY. M. Di Giulio, E. Di Campli, S. Di Bartolomeo, V. Cataldi, L. Marzio, L. Grossi, A.F. Ciccaglione, A. Nostro, L. Cellini. Scand J Gastroenterol 2016;51, 3:263-9.

230. USO DI GOLIMUMAB IN PAZIENTE AFFETTA DA RETTOCOLITE ULCEROSA STEROIDO-DIPENDENTE. L. Grossi, R.Tavani. C Di Giacomo. Terapia Evidence Based 2016; 9, 1: 5-8 Springer Healthcare ISBN 9788867562848

231. THE VALUE OF CONTRAST ENHANCED ENDOSCOPIC ULTRASOUND IN THE FINE NEEDLE ASPIRATION. R Tavani, M. Spezzaferro, A. Della Sciucca, L. Grossi, A.F. Ciccaglione, L. Marzio. Dig Liv Dis 2016; 48Suppl2:e72(abst)

232. CLINICAL AND ECONOMIC EFFECT OF SHORT INFLIXIMAB INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTRE STUDY. M. Cappello, G. Costantino, A.C. Privitera, F. Bossa, A. Lauria, L. Grossi, M.B. Principi, N. Della Valle, M.A. Veneziano, D. Crocchiolo. J Crohn's and Colitis 2016;10, S1: S256(abst)

233. RIFABUTIN CONTAINING TRIPLE THERAPY AND RIFABUTIN WITH BISMUTH CONTAINING QUADRUPLE THERAPY FOR THIRD-LINE TREATMENT OF HELICOBACTER PYLORI INFECTION: TWO PILOT STUDIES. Ciccaglione AF, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Helicobacter. 2016;21(5):375-81. doi: 10.1111/hel.12296. PMID:26807668

234. ESOFAGITI NON DA REFLUSSO. L. Grossi, A. Federico. In: Manuale di Gastroenterologia. Editrice Gastroenterologica Italiana, Edizione 2016-2019:11-14. ISBN 978-88-490-0563-9

2017.

235. CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB ONE-HOUR INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY. Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. World Journal of Gastrointestinal Pharmacology and Therapeutics 2017; May 6;8(2):131-6

236. SPONTANEOUS OPENING OF LES IN ACHALASIA: AN UNCOMMON ON-LINE DOCUMENTATION BY HIGH-RESOLUTION MANOMETRY Grossi L, Ciccaglione AF, Marzio L. JSM Gastroenterol Hepatol 2017: 5(1): 1075.

237. EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC) S. Cocciolillo, F. Ciccaglione, L. Grossi, L. Marzio. Digestive and Liver Disease, 2017, Vol. 49, Suppl. 2: e194–e195 (abst)

238. SYMPTOM PATTERN IN FUNCTIONAL DYSPEPSIA AND GASTROESOPHAGEAL REFLUX DISEASE: ROLE OF H. PYLORI INFECTION R. Tavani, A.F. Ciccaglione, S. Cocciolillo, A. Sepe, M. Di Berardino, C. Di Giacomo, V. Vecchione, L. Grossi, L. Marzio. Digestive and Liver Disease, Vol. 49, Suppl. 2: e143–e144 (abst)

239. THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD) L. Marra, A.F. Ciccaglione, R. Tavani, S. Cocciolillo, A. Sepe, M. Di Berardino, C. Di Giacomo, V. Vecchione, L. Grossi, L. Marzio. Digestive and Liver Disease, Vol. 49, Suppl. 2: e131(abst)

240. ESOPHAGITIS AND ITS CAUSES: WHO IS "GUILTY" WHEN ACID IS FOUND "NOT GUILTY"? Grossi L, Ciccaglione AF, Marzio L. World Journal of Gastroenterology 2017; 7,23(17):3011-16

241. EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC). S Cocciolillo, R. Tavani, M. Di Berardino, A. Sepe, A.F. Ciccaglione, L. Grossi, L. Marzio. Gastroenterology 2017; 152:5 (Suppl):S215 (abst)

242. PRUCALOPRIDE ACCELERATES GASTRIC AND SMALL BOWEL TRANSIT TIMES OF VIDEOCAPSULES ENDOSCOPY. A. Sepe, V. Vecchione M. Di Berardino, R. Tavani, C Di Giacomo, A.F. Ciccaglione, S. Cocciolillo, L. Grossi, L. Marzio. Gastroenterology 2017; 152:5 (Suppl):S1033-S1034 (abst)

243. THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD). L. Marra, A.F. Ciccaglione, A. Sepe, R. Tavani, S. Cocciolillo, M. Di Berardino, C. Di Giacomo, V. Vecchione, L. Grossi, L. Marzio. Gastroenterology 2017; 152:5 (Suppl):S131

244. GOLIMUMAB IN ULCERATIVE COLITIS. REAL-LIFE PROSPECTIVE COHORT STUDY FROM A SINGLE REFERRAL CENTRE OF MIDDLE ITALY. L. Grossi, V. Vecchione, S. Cocciolillo, R. Tavani, M. Di Berardino, A. Sepe, C. Di Giacomo, N. Russo, V. D'Addetta, L. Marzio. United European Gastroenterology Journal 2017; 5(S1): A304 (abst)

245. EFFICACY AND SAFETY OF GOLIMUMAB IN ULCERATIVE COLITIS. PRELIMINARY DATA FROM A MULTICENTER ITALIAN STUDY. F. Bossa, M.R. Valvano, C. Giuseppe, A. Lauria, N. Bucciante, E. Vinci, E. Shaini, M. Mendolaro, L. Grossi, S. Mazzuoli, A. Rispo, G. Pranzo, L. Sebkova, A. Tursi, A. Miranda, M. Patturelli, R. Spagnuolo, C. Ricciardelli, C. Sgarro, P. Paese, G. Insera, A. Azzarone, W. Fries, A.C. Privitera, M. Principi, M. Cappello, A. Andriulli. United European Gastroenterology Journal 2017; 5(S1): A527 (abst)

246. REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). D. Pugliese, A. Variola, A.C. Privitera, M. Allocca, F. Bossa, M. Cappello, G. Lorenzon, S. Mazzuoli, M. Principi, R. Sablich, A. Ferronato, S. Festa, L. Moser, G. Tapete, G. Bodini, M. Di Girolamo, L. Grossi, F. Mocciano, C. Ricci, S. Saibeni, R. Spagnuolo, E. Capoferro, A. Armuzzi. United European Gastroenterology Journal 2017; 5(S1): A750 (abst)

247. USO DI GOLIMUMAB COME SECONDA LINEA BIOLOGICA IN UN PAZIENTE CON RETTOCOLITE ULCEROSA. L. Grossi, V. Vecchione. Terapia Evidence Based 2017;10, 3:16-19 Springer Healthcare ISBN 9788867563036

2018.

248. FABRIC PHASE SORPTIVE EXTRACTION-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-PHOTO DIODE ARRAY DETECTION METHOD FOR SIMULTANEOUS MONITORING OF THREE INFLAMMATORY BOWEL DISEASE TREATMENT DRUGS IN WHOLE BLOOD, PLASMA AND URINE. A. Kabir, K.G. Furton, N. Tinari, L. Grossi, D. Innosa, D. Macerola, A. Tartaglia, V. Di Donato, C. D'Ovidio, M. Locatelli. Journal of Chromatography B 2018; 1084:53-63.

249. EFFICACY OF TREATMENT WITH PYLERA IN COMBINATION WITH RANITIDINE ON FIRST-LINE INFECTION HELICOBACTER PYLORI: EXPERIENCE OF A SINGLE CENTER. A.F. Ciccaglione, V. Vecchione, N. Russo, C. Di Giacomo, L. Grossi, L. Marzio. Dig Liv Dis 2018, 50 Suppl 2:e122

250. FUSOBACTERIUM NUCLEATUM (FN) IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE. A. D'Amico, L. Cellini, M. Di Giulio, M. Basti, A.F. Ciccaglione, L. Grossi, L. Marzio. Dig Liv Dis 2018, 50 Suppl 2:e139

251. ESOPHAGEAL MOTILITY ASSESSMENT AFTER PRUCALOPRIDE ADMINISTRATION IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY (IEM) AND SYSTEMIC SCLEROSIS. A.L. Taraschi, A.F. Ciccaglione, V. Vecchione, C. Di Giacomo, N. Russo, L. Grossi, L. Marzio. Dig Liv Dis 2018, 50 Suppl2:e89

252. COMBINED VIDEOCAPSULE ENDOSCOPY (VCE) AND LACTULOSE HYDROGEN BREATH TEST (LHBT): A COMPARATIVE STUDY TO ASSESS ORO-CECAL TRANSIT TIME (OCTT). E. Aceto, A.F. Ciccaglione, V. Vecchione, N. Russo, C. Di Giacomo, V. D'Addetta, L. Grossi, L. Marzio. Dig Liv Dis 2018, 50 Suppl2:e210

253. REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). D. Pugliese, F. Rogai, A. Variola, A. Viola, A.C. Privitera, M. Allocca, F. Bossa, M. Cappello, G. Lorenzon, S. Mazzuoli, M.B. Principi, R. Sablich, A. Ferronato, S. Festa, L. Moser, G. Tapete, G. Bodini, M. Di Girolamo, L. Grossi, G. Mocchi, F. Mocciano, C. Ricci, S. Saibeni, R. Spagnuolo, C.C. Cortellezzi, B. Orlandini, E. Capoferro, G. Costantino, A. Armuzzi. Dig Liv Dis 2018, 50 Suppl2:e136

2019.

254. LA MALATTIA DAREFLUSSO GASTROESOFAGEO. L. Grossi, S. Ardizzone. In Malattie dell'Apparato Digerente, Edizione 2019-2022. Editrice gastroenterologica Italiana: 43-48.

255. GASTRO-ESOPHAGEAL REFLUX DISEASE. L. Grossi, S. Ardizzone. In: Digestive Diseases, 2019-2022 Editionè, Editrice Gastroenterologica Italiana: 39-43.

256. USE OF BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE: A POSITION UPDATE OF THE ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD): G. Fiorino, F. Caprioli, M. Daperno,....L. Grossi, G. Vitale, G. Zoli. Digestive and Liver Diseases, 2019;51,5:632-9

2020.

257. REAL-LIFE EFFECTIVENESS AND SAFETY OF GOLIMUMAB AND ITS PREDICTORS OF RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS F. Bossa, G Biscaglia, MR Valvano, G Costantino, A Lauria, R Clemente, C Ferracane, E Shahini, M Mendolaro, L. Grossi, S Mazzuoli, A Rispo, G Pranzo, L Sebkova, A Tursi, A Miranda, M Patturelli, R Spagnuolo, C Ricciardelli, C Sgarro, P Paese, G Inserra, A Azzarone, O Nardone, W Fries, N Buccianti, A C Privitera, M B Principi, M Cappello, F W Guglielmi, M Romano, G Riegler, L Fanigliulo, R Melina & A Andriulli. Dig Dis Sci 2020;65,6:1767-76 doi:10.1007/s10620-019-05904-z IF 2.937

258. STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT. D. Pugliese, G. Privitera, A. Armuzzi, L. Grossi as part of the LIVE IG-IBD study group. Journal of Crohn's and Colitis 2020; 14, S1: S419 (abst)

259. OUTCOMES OF COVID-19 IN 79 PATIENTS WITH IBD IN ITALY: AN IG-IBD STUDY. C. Bezzio, S. Saibeni, A. Variola, M. Allocca, A. Massari, V. Gerardi, V. Casini, C. Ricci, F. Zingone, A. Amato, F. Caprioli, M. V. Lenti, C. Viganò, M. Ascolani, F. Bossa, F. Castiglione, C. Cortellezzi, L. Grossi, M. Milla, D. Morganti, L. Pastorelli, D.G. Ribaldone, A. Sartini, A. Soriano, G. Manes, S. danese, M. Fantini, A. Armuzzi, M. Daperno, G. Fiorino, on behalf of Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Gut 2020; doi:10.1136/gutjnl-2020-321411

260. TELEMEDICINE AND REMOTE SCREENING FOR COVID-19 IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS FROM THE SOCOVID-19 SURVEY. Massimo Caludio Fantini, Livia Biancone, Gabriele Dragoni, Cristina Bezzio, Agnese Miranda, Davide Giuseppe Ribaldone, Angela Bertani, Fabrizio Bossa, Mariangela Allocca, Andrea Buda, Giammarco Mocchi, Alessandra Soriano, Francesco William Guglielmi, Lorenzo Bertani, Flavia Baccini, Erica Loddo, Antonino Carlo Privitera, Alessandro Sartini, Angelo Viscido, Laurino Grossi, Valentina Casini, Viviana Gerardi, Marta Ascolani, Mirko Di Ruscio, Giovanni Casella, Edoardo Savarino, Davide Stradella, Rossella Pumpo, Claudio Camillo Cortelezzi, Marco Daperno, Valeria Ciardo, Olga Maria Nardone, Flavio Caprioli, Giovanna Vitale, Maria Cappello, Michele Comberlato, Patrizia Alvisi, Stefano Festa, Michele Campigotto, Giorgia Bodini, Paola Balestrieri, Anna Viola, Daniela Pugliese, Alessandro Armuzzi, Simone Saibeni, Gionata Fiorino
Inflamm Bowel Dis 2020; doi:10.1093/ibd/izaa254

261. ACTIVITIES RELATED TO INFLAMMATORY BOWEL DISEASE MANAGEMENT DURING AND AFTER THE CORONAVIRUS DISEASE 2019 LOCKDOWN IN ITALY: HOW TO MAINTAIN STANDARDS OF CARE. S. Saibeni, L. Scucchi, G. Dragoni, L. Grossi, ..M.C. Fantini, G.Fiorino. United European Gastroenterology Journal 2020; 8,10:1228-35

2021

262. INFLUENCE OF THE COVID-19 OUTBREAK ON DISEASE ACTIVITY AND QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE PATIENTS. C. Conti, I. Rosa, L. Zito, L. Grossi, K. Efthymakis, M. Neri, P. Porcelli. Psychiatry 2021, 12:664088. doi: 10.3389/fpsy.2021.664088 "Open Access"

263. TWO-YEAR EFFECTIVENESS AND SAFETY OF GOLIMUMAB IN ULCERATIVE COLITIS: AN IG-IBDSTUDY. Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocchi G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocchiario F, Rizzello F, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).United European Gastroenterol J. 2021 Feb;9(1):102-109. doi: 10.1177/2050640620974308. Epub 2021 Mar 1.

264. THERAPIES FOR INFLAMMATORY BOWEL DISEASE DO NOT POSE ADDITIONAL RISKS FOR ADVERSE OUTCOMES OF SARS-COV-2 INFECTION: AN IG-IBD STUDY. C. Bezzio, A. Armuzzi,L. Grossi, ...F. S. Conforti. Aliment Pharmacol Ther 2021;54:11-12:1432-44.

2022

265. EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN A MATCHED COHORT OF ELDERLY AND NONELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE IG-IBD LIVE STUDY. D. Pugliese, G. Privitera, ...L. Grossi, A. Armuzzi. Aliment Pharmacol Ther 2022: 56:95-109

266. OBJECTIVE COMPARISON OF VEDOLIZUMAB AND USTEKINUMAB EFFECTIVENESS IN CROHN'S DISEASE PATIENTS FAILURE TO TNF-ALPHA INHIBITORS. Onali S, MD, PhD, Pugliese D MD, PhD, Caprioli FA MD, PhD, Orlando A4MD, Biancone L MD, PhD, Nardone OM MD, Imperatore NMD, Fiorino G MD, PhD, Cappello M MD, Viola A MD, Principi MB MD, PhD, Bezzio C MD, Aratari A MD, Carparelli S MD, Mazzuoli S MD, Manguso F MD, PhD, Grossi L MD, PhD, Bodini G MD, PhD, Ribaldone D MD, Mocci G MD, Miranda A MD, Minerba L MD, PhD, Favale A MD, Grova M MD, Scucchi L MD, Segato S MD, Fries W MD, PhD, Castiglione F MD, PhD, Armuzzi A MD, PhD, Fantini MC1 MD, PhD on behalf of the IG-IBD. Am J Gastroenterology 2022. Doi: 10.14309/ajg000000000001773